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ABSTRACT 
Umbilical cord blood (UCB) is an alternative graft source in allogeneic hematopoietic stem 
cell transplantation (HSCT). The unique advantages with UCB as a stem cell source are 
found in the permissibility for human leukocyte antigen (HLA)-mismatch, rapid availability, 
and comparatively risk-free graft collection. Important drawbacks to UCBT are delayed 
engraftment, poor immune reconstitution and the lack of donor cells for post-transplant 
therapy. In this thesis we aimed to: 1) evaluate clinical outcome and chimerism development 
after UCBT, and 2) develop treatment alternatives to donor lymphocyte infusions (DLI) for 
UCBT recipients.  
In scientific paper I, we performed a retrospective single-center analysis of chimerism 
development and clinical outcome in 50 single and double UCBTs (DCBTs) in children and 
adults with hematological malignancies and non-malignant diseases. Complete donor 
chimerism was found to be associated with total body irradiation. A negative correlation was 
seen between 5-year survival and age, acute graft-versus-host disease (GVHD) grades III-IV, 
and mesenchymal stem cell (MSC) treatment. In scientific paper II, we focused on 
chimerism development in seven patients undergoing DCBT. Two patients developed long-
term mixed donor–donor chimerism (MDC) in all cell lineages, at 25 and 35 months after 
DCBT. The work in scientific paper III was performed to study the immunological 
phenotype and function of these patients with MDC. We found that there were differences 
between the engrafted units: one unit had more naïve, less functional T-cells and more NK-
cells. When the patients with MDC were compared with patients with single UCB unit 
chimerism, they had a more naïve T-cell profile. The results also indicated that inter-unit 
matching of the HLA-C genes and high-dose anti-thymocyte globulin (ATG) might influence 
MDC development after DCBT. We have expanded T-cells from clinical cord blood grafts 
with anti-CD3+/CD28+ beads and interleukin (IL)-2 for possible use as alternative DLI. In 
scientific paper IV we studied the effect of adding IL-7, and found that it conferred a greater 
proliferation rate, higher CD4+/CD8+ ratio, and less central memory T-cells. We also noticed 
a higher percentage of polyfunctional T-cells with IL-7. The cultured UCB DLI has been 
used clinically in four patients with mixed chimerism (MC), minimal residual disease (MRD) 
and graft failure without certain adverse effects. The results were presented in scientific 
paper V. In the patient treated due to MRD, the malignant cell clone was undetectable at 
treatment and for 3 months after infusion. In one patient with MC, the percentage of recipient 
cells decreased in temporal association to the treatment. These events indicate possible 
treatment benefits, but without certain causal association to UCB DLI treatment. 
In summary, we found that MSC treatment was negatively correlated to survival in our 
UCBT recipients. High-dose ATG and HLA-C match might predispose for MDC. Cultured 
UCB DLI products are feasible to produce, and have been used in patients with no certain 
adverse effects, but with possible benefits.  
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I. INTRODUCTION 
Signs of disease in ancient remains, e.g. findings of malaria, tuberculosis and cancer in 
Egyptian mummies (1), illustrate the integral role diseases have played in human life over 
past millennia. The disease-mediated impact on the health and life expectancy of human 
beings is severe, but has been considerably ameliorated by the medical breakthroughs and 
improved nutrition of recent centuries. Today, effective treatments and vaccines are available 
for many common diseases, and the knowledge of human illnesses is continuously increasing. 
However, there are still areas where the extent of medical progress is insufficient. The aim of 
this thesis was to address a subject found in one of these medical areas, namely allogeneic 
hematopoietic stem cell transplantation (HSCT) with umbilical cord blood (UCB). This is an 
effective treatment for several malignant and non-malignant diseases, but limited by severe 
toxicities and a substantial risk of treatment failure. 
The indications for HSCT are heterogeneous, and include several congenital conditions and 
hematological malignancies (2-4). These diseases all currently lack other satisfactory and 
effective treatments unassociated with severe toxicity. The rationale behind HSCT is to 
exchange the affected hematopoietic system of a patient for a healthy one transplanted from a 
donor. For the inborn diseases, this change of the origin of hematopoiesis is sufficient for a 
cure. However, the treatment principle is more complex in hematological cancers. In this 
patient group, the cure is achieved by a combination of chemotherapy-mediated reduction of 
cancer cells, replacement of the malignantly transformed hematopoiesis and an 
immunologically mediated graft-versus-tumor (GVT) effect. The donor immune system is 
here required to exert alloreactivity, which signifies an immune reaction towards recipient 
cells (5).  
HSCT is known to be associated with important limitations. The applicability is limited by 
the requirement of a donor matched for certain highly polymorphic genes (6, 7). There are 
also severe morbidity and mortality associated with HSCT (4, 8). UCB is a relatively new 
source of grafts for HSCT with unique properties that have been used to improve the 
applicability of HSCT. However, umbilical cord blood transplantation (UCBT) is associated 
with drawbacks such as poor immune reconstitution and a lack of donor cells for post-
transplantation adoptive therapies (9-11). To increase the applicability and success of HSCT 
and UCBT, it is necessary to increase the knowledge of immune mechanisms involved in 
stem cell transplantation and of how these mechanisms can be favorably manipulated. 
The studies described in this thesis have all been performed at the Center for Allogeneic Stem 
cell Transplantation (CAST) at the Karolinska University Hospital Huddinge, Stockholm, 
Sweden. Mentions in the text of local medical practices and CAST are references to this 
clinic and its practices. 
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I.1 THE IMMUNE SYSTEM 
I.1.i A short introduction to the immune system 
The immune system is essential to protect human beings against the microbes and viruses in 
the surrounding environment. It consists of a complex network of cells and molecules that 
together combat infectious pathogens. The necessity of the immune system for human 
survival is dramatically illustrated in individuals with immune deficiencies and human 
immunodeficiency virus infection (HIV), where the lack of an immune defense permits 
relatively harmless viruses and microorganisms to cause devastating infections (12, 13). 
Genetic findings suggest that humans and pathogens have developed side by side, with 
infection-related mortality driving a process of natural selection that has shaped the immune 
system in its present form (14). The immune system not only conveys protection against the 
microbes in the environment; it is also necessary for a peaceful co-existence with the 
microbial flora in the gastrointestinal tract and on the skin, among other sites (15). The 
immune system also exercises a degree of protection against the development of cancer. 
Transformed cells are recognized by the immune system, which can cause their eradication 
by immune-mediated mechanisms (16, 17). The same system that provides protection against 
infections and tumors can unfortunately also mediate damage when activated against the 
incorrect targets. This is the cause of autoimmune diseases such as Crohn’s disease (18) and 
rheumatoid arthritis (19), where normal structures in the bowel and joints are targeted by the 
immune system. Another instance of incorrect immune activation towards harmless 
substances is found in allergy (20).  
The immune system is a collective term for all the cells, tissues and molecules that co-operate 
in an immune reaction, the process with which the defense against infection is performed. 
The immune system is classically divided into two sections, the innate, or native, system and 
the adoptive system. A schematic illustration of the immune system and its two sections is 
found in Figure 1.  
The first encounter with a pathogen is normally handled by the innate system. Innate 
immunity comprises the physical barriers of the body, antimicrobial substances produced at 
the barriers and systemically, antigen-presenting cells (APCs), and effectors cells (20). The 
most striking characteristic of the innate immune response is the immediate nature of its 
activation. This is possible due to the inborn, conserved mechanisms used in the innate 
system to recognize pathogens. The major functions of the innate immunity can be divided 
into three parts: 1) Keep intruders out. 2) Kill the intruders that do pass the barrier. 3) Raise 
the alarm for additional help if the situation cannot be easily resolved. An infecting pathogen, 
e. g. a virus, bacteria or fungi, first has to pass one of the body’s barriers; the mucosa of the 
mouth, gastrointestinal tract, genitalia or lungs, and remain unharmed through exposure to the 
antimicrobial substances excreted there. If a pathogen penetrates the barrier successfully, the 
next obstacle is the complement system, a set of plasma proteins that function by the 
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recruitment of phagocytic cells, the induction of phagocytosis of pathogens, and by direct 
lysis of microbial cells (20). The immune system launches phagocytic cells to clear the 
pathogens by ingestion and destruction. The phagocytes also produce cytokines to summon 
other immune effector cells. Intracellular pathogens are difficult to clear by phagocytosis. 
This type of pathogen can be effectively eradicated by natural killer (NK)-cells, as they have 
the ability to kill infected cells. This prevents the spread by destroying the reservoirs of 
intracellular pathogens.  
The second part of the immune system, the adaptive immunity, cannot respond with the same 
rapidity as the innate system in consequence of the antigen-specific nature of its response. 
The adaptive immune system is activated by the innate system via APCs or, more rarely, by 
antigens binding directly to the receptors of adaptive immune cells, which are produced by 
random gene rearrangement, making every receptor unique (20). The cellular agents of 
adaptive immunity are the T-cells and the B-cells. Their effector functions include antigen-
specific killing of infected cells and microbes, antibody production, and cytokine production. 
The activation of the adaptive effectors occurs in the secondary lymphoid organs: the lymph 
nodes, the spleen and the mucosa-associated lymphoid tissues. Pathogens and APCs travel to 
these tissues to activate antigen-inexperienced T- and B-lymphocytes, which then proliferate 
and differentiate into effector cells (20). These then travel via the blood to the infection site. 
The adaptive arm of the immune system also provides immunological memory. This memory 
function enables the immune system to respond quickly and efficiently to the pathogen if 
Innate'
immunity'
An2genB'
presen2ng''
cells:''
macrophages,'
neutrophils'
NKBcells'
Physical'
barriers'
Complement'
Eosinoﬁls,'
Basophils,'
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Adap2ve'
immunity'
TBcells' BBcells'
The'Immune'system'
Immunity 
MHC'
Figure 1. Figure 1: A schematic representation of the immune system’s two sections. The MHC molecules form a 
bridge between the two compartments, as antigens need to be presented on these molecules for activation of the 
adaptive system.  
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encountered a second time. Immunological memory is also the mechanism that enables 
vaccination.  
Communication between different sections of the immune system is necessary for successful 
eradication of pathogens. The molecules that are mainly responsible for the activation of the 
adaptive system by binding to receptors on adaptive cells are called major histocompatibility 
antigens (MHC) or human leukocyte antigens (HLA). They function by presenting parts of 
pathogen-derived proteins (peptides), to T-cells. The T-cell receptor (TCR) can only 
recognize pathogen-derived peptides if they are presented on a MHC molecule, which means 
that T-cell-mediated immunity against infection only can be induced by the presentation of 
pathogen-derived peptides on MHC molecules (20, 21). MHC molecules are categorized into 
two classes: class I and class II. A MHC class I molecule is made up by a α-chain that forms 
the peptide-binding structure, and a supporting protein called β2-microglobulin (20, 21). The 
MHC class I molecules are expressed on practically all nucleated cells, and presents peptides 
derived from protein breakdown in the cytoplasm of cells. The presented peptides reflect the 
intracellular processes of the presenting cell, and thus also if an intracellular infection is 
present (20, 21). MHC class I molecules bind specifically to the TCRs of CD8+ cytotoxic T-
cells, which have the ability to kill infected cells upon presentation of pathogen-derived 
peptides on MHC class I molecules (20, 21). MHC class II molecules consist of two 
proteins, a α-chain and a β-chain, which together form the peptide-binding domain of the 
molecule. This class of MHC is expressed on APCs. The APCs present peptides on MHC 
class 2 molecules to CD4+ T-helper cells that on activation produce cytokines and provide 
co-stimulation to propagate the immune reaction (20). The MHC, or HLA, genes are also the 
most important to match between donor and recipients in HSCT, which will be discussed 
below.  
I.1.ii A presentation of the components of the immune system 
The white blood cells are the central actors of the immune system. They all develop from 
hematopoietic progenitor cells in the bone marrow. A simplified model of their development 
is shown in figure 2. 
The epithelial cells of the physical barriers (the skin and the mucosa of the mouth, lungs, 
gastrointestinal tract, and urinary tract) tightly adhere to each other to prevent the passage of 
microbes and particles, and produce antimicrobial peptides that can kill certain types of 
bacteria (20). 
The effector cells of the innate immune response can be divided into several categories with 
distinct function. The phagocytes, neutrophil granulocytes, monocytes and macrophages, 
exert their functions partly by ingesting pathogens, known as phagocytosis. Ingestion is 
triggered by receptors on the surface of the phagocyte binding to pathogens (20, 21). This 
group of receptors is called pathogen recognition receptors. This group is further divided into 
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subgroups such as scavenger receptors, Toll-like receptors, NOD-like receptors, and RIG-like 
receptors. They recognize constituents of the bacterial cell wall, bacterial flagella, virus RNA 
and DNA, and other pathogen-associated particles (20). Neutrophils are usually the first cell 
type to respond to signals of local infection. They migrate through the capillary walls to the 
tissues in response to changes in the endothelial cells of the vessel wall. In the affected tissue, 
they ingest and destroy microbes, and also partake in the clearing of debris, such as dead cells 
and microbes (20). Macrophages have a similar role, but they also produce cytokines, a type 
of signal substances crucial to the coordination of the immune system. Macrophages also co-
operate with the adaptive immune system by antigen-presentation of ingested pathogens to 
lymphocytes on MHC class II and by phagocytosis of antibody-covered targets (20). 
Antigen-presenting cells are one of the links between innate and adaptive immunity, and 
exert this function by presenting parts of digested antigens to adaptive immune cells on MHC 
molecules. The Dendritic cell is a professional APC that is found in peripheral tissues, 
functioning as a sentinel. Dendritic cells are activated upon ingestion of pathogens and 
responds by producing inflammatory cytokines, and migrating to a lymph node to present the 
captured pathogen to lymphocytes (20). 
The last of the cell types in the innate immune system that will be presented in this brief 
introduction is the NK-cell. This cell is special both in function and mechanism of activation. 
Normal'human'Hematopoiesis'
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Figure 2. A simplified model of human hematopoiesis. 
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The NK-cells express a number of inhibitory and activating receptors, and the resulting 
activation or inhibition of the cell is determined by the sum of the signals transmitted through 
the receptors. NK-cells are central in virus defense by their killing of infected cells, thus 
eradicating intracellular virus reservoirs. They can also recognize and kill certain types of 
malignant cells by their lack of ligands for the inhibitory receptors (20).  
Two main cell types make up the adaptive immune defense: B-cells, and T-cells. The B-cells 
express antigen-specific B-cell receptors able to recognize a variety of pathogen-associated 
antigen types, such as proteins, polysaccharides and lipids. The receptor genes are randomly 
rearranged during B-cell development, resulting in an extremely diverse repertoire of antigen 
specificities (20). After activation, a modified soluble form of the B-cell receptor is excreted 
as a circulating antibody. The antibodies function by activation of the complement system, by 
binding to pathogens, and triggering their phagocytosis or destruction, or by neutralizing 
pathogens by binding to and blocking important molecules on their surface (20). 
T-cells are central to this thesis, and their development and function will be described in 
more detail in the next section. Briefly, the function of T-cells can be divided into two major 
categories by their expression of the co-receptors CD4 and CD8. The T-cells expressing CD4 
are designated helper cells and mainly function through co-ordination of the immune 
response by cytokine production and co-stimulation of other effector cells, such as 
macrophages, eosinophil granulocytes and B-cells. The functions of CD8+ T-cells are similar 
to NK-cells, but are orchestrated through the presentation of foreign peptides on MHC class I 
molecules. When the T-cell receptor binds to an MHC class I molecule holding the 
appropriate peptide, they can kill infected or transformed cells. 
I.1.iii The development and function of T-cells  
T-cells have several diverse functions in the immune system. The broad division of T-cells 
into CD4+ helper cells and CD8+ cytotoxic cells can be further subdivided according to their 
expression of other markers and transcription factors. The CD4+ T-cell compartment is 
highly diverse, and different types of CD4+ T-helper (Th) cells are adapted to optimally 
respond to different pathogens (22, 23). The subset of the naive CD4+ T-cells is decided by 
the signals in the surrounding milieu during their priming, and the nature of these signals 
depends on the infecting pathogen. This enables development of Th subsets suited to 
infecting pathogens. The best-described Th subsets are the Th1, Th2, Th17 and follicular 
helper T-cells (20, 23). Regulatory T-cells are also a subset of the CD4+ T-cell family 
Th1 cells are described to mainly focus on intracellular pathogens: intracellular bacteria and 
viruses. They are generated when naive T-cells are primed in the presence of interleukin (IL)-
12. They are characterized by expression of a transcription factor named T-bet and 
production of interferon (IFN)-γ, which activates macrophages to destroy intracellular 
bacteria (23-25). 
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Th2 T-cells are important in immunity against extracellular parasites like worms (23). They 
are also thought to interact with B-cells to induce antibody class switching, especially to 
immunoglobulin (Ig) E, which is associated with immune responses to parasites (22). Th2 
cells are also involved in allergy and asthma (23, 26). The Th2 subset is induced when naive 
T-cells are primed in the presence of IL-4. They are characterized by expression of the 
transcription factor GATA-3. Th2 cells mainly produce the cytokines IL-4, IL-5 and IL-13 
(23, 27). 
Th17 subset is important in immune responses against fungi and extracellular bacteria. They 
express the transcription factor RORγ that is responsible for the production of IL-17 (23, 28). 
IL-17 acts via epithelial cells to attract neutrophils to the site of infection (23). RORC also 
induces the expression of chemokine receptor (CCR) 6, which is important to guide the Th17 
cells to the site of infection (29). Th17-mediated immunity is also thought to be implicated in 
certain autoimmune diseases (30).  
T follicular helper cells are located in the lymph nodes in close proximity to B-cell germinal 
centers. They promote proliferation and differentiation of antigen-specific B-cells. The 
inducible co-stimulator (ICOS), a classic CD28 family co-stimulatory molecule, has been 
found to be important for the follicular recruitment of activated T-helper cells in mice (31).  
One CD4+ T-cell subset, the regulatory T-cells, has very distinct functions from the others 
subsets. They negatively regulate the activity of other T-cells. They are usually characterized 
by the expression of high levels of the IL-2 receptor α-chain and a transcription factor called 
forkhead box protein 3 (FoxP3). Unfortunately, these markers are also found on activated 
CD4+ effector T-cells, which can make their identification in cell cultures difficult. There are 
several other markers that also characterize regulatory T-cells, but most are expressed also by 
other subsets (32, 33).  
The CD8+ T-cell subset is more homogenous than the CD4+ subset. The CD8+ T-cells are 
all capable of mediating cellular cytotoxicity, e g killing of cells expressing an MHC class I 
molecule with a peptide of the correct specificity. They are characterized by the expression of 
the transcription factor forkhead box protein O1 (FoxO1) (34). Activation of CD8+ T-cells 
requires a stronger signal than CD4+ T-cells, possibly due to the destructive property of their 
effector functions. They are activated either by a combination of MCH: TCR signalling and 
stimulation by CD4+ helper T-cell, or by binding to MHC class II molecules on activated 
APCs, that also express co-stimulatory molecules. The combination of TCR-mediated 
stimulation and additional signals in the form of co-stimulation is then sufficient for their 
activation (22). 
The development of the T-cells begins in the bone marrow. They then migrate to the thymus 
at the stage of progenitor cells. The thymus is an organ located close to the heart, which is 
specialized in the development and “education” of T-cells (35, 36). Here, the cells are 
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committed to the T-cell lineage, and the gene rearrangement of the T-cell receptor takes 
place. This process is called VDJ recombination and comprises the random combination of 
different versions of three gene segments and additional changes in the junctions connecting 
the segments (20, 35). The rearrangements enable the production of up to1016 different TCRs 
(20). Two different protein chains make up the TCR (22). In the majority of the T-cells, also 
called conventional T-cells or TCR αβ T-cells, there is one α-chain and one β-chain. The 
TCR αβ recognizes peptides presented by MHC molecules (22). A minority of T-cells 
expresses a TCR with one γ-chain and one δ-chain. These recognize non-typical antigens, 
like the phospholipids on mycobacteria (37).  
During the receptor gene rearrangement, the T-cells begin to express both the CD4 and CD8 
co-receptors and are termed "double-positive thymocytes" (CD4+CD8+) (35). After the 
receptor rearrangement, the double-positive thymocytes undergo a selection process in two 
steps: positive selection and negative selection. In positive selection, the thymocytes are 
exposed to self-antigens presented to them by thymic epithelial cells. These epithelial cells 
are induced by the transcription factor autoimmune regulator (AIRE) to present a majority of 
the self-peptides that T-cells are likely to encounter in the body (35). The survival of the 
thymocytes depends on the appropriate binding of their TCR to peptide-loaded MHC 
molecules. If the TCR fail to bind, or bind too weakly, to MHC: antigen complexes, the 
thymocyte undergoes neglect-induced cell death, or apoptosis. This is due to thymocyte 
survival being dependent on TCR-mediated signaling. This process is called positive 
selection, and prevents development of T-cells incapable of MHC-mediated activation (20). 
After positive selection, the thymocytes express either CD4 or CD8, according to the class of 
MCH of the MHC-peptide complex they have recognized. CD4 is expressed if the TCR binds 
to a peptide-bearing MHC class II molecule, and CD8 is expressed if it recognized a peptide-
binding MHC class I molecule (22, 35). The T-cells are then termed “single-positive 
thymocytes”.  
Negative selection is a process where thymocytes that bind too strongly to MHC-antigens 
complexes are eliminated by apoptosis to protect the organism from autoimmunity (22, 35). 
Negative selection can occur during positive selection: the degree of affinity to self-
antigen:MHC complexes is thought to decide whether the thymocyte is positively selected to 
survive (lower affinity) or negatively selected to become apoptotic (higher affinity) (20). 
Negative selection can also occur when single-positive thymocytes that have successfully 
undergone positive selection encounter bone marrow-derived APCs in the marrow of the 
thymus. These APCs express co-receptors, and the combination of a strong TCR affinity to a 
self-antigen: MHC complex and co-stimulation also eliminate self-reactive single-positive 
thymocytes (20). The thymocytes that successfully undergo positive and negative selection 
leave the thymus as naïve T-cells, ready to partake in an immune response. 
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During an immune response, 
naïve T-cells are activated to 
proliferate, and differentiate into 
effector cells. T-cell immune 
reaction follows a distinct kinetic 
pattern, as is shown in the top 
panel of Figure 3. During the 
activation process, different 
activation markers are up-
regulated in a tightly controlled 
procession (21), as is shown in the 
lower panel in Figure 3. This 
enables determination of the 
activation status of T-cell 
populations. In a successful T-cell 
response, T-cell numbers reach a 
peak after approximately one 
week. Then, when the infection is 
resolved, the contraction phase 
begins. A majority of the effector T-cells undergo apoptosis, as they are no longer necessary 
to control the infection (38). Activation in itself drives a propensity for apoptosis by up-
regulation of receptors for apoptosis induction and changes in gene regulation towards a pro-
apoptotic profile (39, 40). Antigen-mediated TCR stimulation, cytokine signaling and co-
stimulation counteract activation-induced apoptosis, which means that the T-cells will receive 
survival signals as long as the immune reaction is actively ongoing, but not when the 
infection is resolved (21, 38).  
A small number of memory T-cells will remain long-term after the infection is resolved. 
These T-cells are, together with memory B-cells, responsible for immunological memory. 
The memory T-cells are primed to rapidly proliferate and differentiate into effector T-cells 
again on a new encounter with the same pathogen. The development of memory T-cells is 
debated, and several models have been described (41). One model of memory development 
suggests that naïve T-cells differentiate into effector cells upon activation, and that memory 
T-cells are developed out of a smaller subset of the effector T-cells during the contraction 
phase of the immune response. A selection process based on fitness or avidity have been 
suggested to decide which effector T-cells that develop into memory T-cells (41, 42). 
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Figure 3. The T-cell immune response. The top panel depicts the 
kinetics of CD4+ and CD8+ T-cell numbers in an immune response. 
The bottom panel shows the kinetics of activation markers in T-cells. 
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Another model have suggested that naïve T-cells differentiate directly into a stem memory T-
cell subset, and then into central memory T-cells, with capacity of proliferation and 
trafficking into lymph nodes. Subsequently, a differentiation into effector memory T-cells, a 
memory subset with some effector function, and a capacity for rapid differentiation into 
effector cells is suggested. This hypothesis is based on the finding of shorter telomeres in 
effector T-cells than in memory T-cells. This could indicate that effector T-cells have 
undergone more numerous cell divisions, and is the later development phase (41, 42). Some 
mechanisms believed to partake in the memory development process, like up-regulation of 
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Figure 5. Definition of memory development stages.  
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Figure 4. Models of memory development. The first model on the left hypothesizes that naïve T-cells 
initially differentiate into memory T-cells and later into effector T-cells, due to the finding that effector T-
cells have the shorter telomeres. The Second model on the right suggests that memory T-cells develop 
from a small subset of effector T-cells during the contraction phase of an immune response.  
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the IL-7 receptor α-chain, and the importance of IL-2 signaling during priming, are discussed 
in the chapters I.1.IV. The two models are pictured in figure 4.  
Expression of cell surface markers CD45RO and CCR7 have been used to characterize 
different subsets of CD3+ T-cells with regard to memory development in this thesis (11, 43, 
44). The following definitions were used: CD45RO- CCR7+ were termed naive T-cells, 
CD45RO+ CCR7+ were considered central memory T-cells, CD45RO+ CCR7- were 
termed effector memory T-cells, and CD45RO- CCR7- were considered as terminally 
differentiated memory T-cells. The definitions are pictured in Figure 5. 
I.1.iv Cytokines: IL-2 and IL-7 
Cytokines are signal molecules essential to hematopoiesis, and to coordination and regulation 
of immune responses. They have various functions in the production, proliferation and 
differentiation of hematopoietic cells. Cytokines stimulate, direct and regulate the 
components of immune reactions to ensure rapid response to pathogens, recruitment of the 
correct responders, and prevent immune-related damage (22). Cytokine signaling directs 
immune responses into the correct path by inducing effector differentiation of selected cell 
types. Disease symptoms and healing may be affected if the path of the immune reaction is 
not optimal. This is seen in Hansen’s disease, where a milder form of the disease is seen in 
patients that respond predominantly with a Th1 response and macrophage activation, 
compared to patients with a response dominated by recruitment of neutrophil granulocytes 
and antibody production by B-cells (45). The effects of cytokines on non-immune cells 
include induction of marker expression on vessel endothelium necessary for trafficking of 
plasma proteins and leukocytes, and acute phase protein production in liver cells. There are 
several categories of cytokines including chemokines, interferons, interleukins and tumor 
necrosis factors. They are known to have both pro-inflammatory and anti-inflammatory 
effects (22). As such, cytokines are clinically important mediators in a wide range of diseases, 
from acute and chronic inflammatory and autoimmune diseases to neurodegenerative disease 
and the joint disease seen in diabetes and obesity (46-49).  
The cytokines that will be in focus in this thesis are IL-2 and IL-7. An introduction into the 
functions of those two cytokines is found below. 
I.1.iv.1 IL-2 
IL-2 was identified in 1976, and was described initially as a T-cell growth factor produced by 
lymphocytes (50, 51). The finding of IL-2 enabled in vitro T-cell culture, which previously 
had not been possible. IL-2 is secreted predominately by activated CD4+ T-cells, but also by 
CD8+ T-cells, NK-cells and activated dendritic cells (51). The IL-2 receptor is made up of 
three distinct subunits, and exist in two different subunit-combinations: a trimeric high-
affinity IL-2 receptor containing the α-chain (CD25), β-chain (CD122), and the common γ-
chain (CD132, also part of the receptors for several other cytokines), or a low-affinity dimeric 
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receptor consisting of only the β- and γ-chains (51, 52). The IL-2 receptor α-chain is present 
as both a membrane and soluble protein (52, 53). Binding of IL-2 to the IL-2 receptor results 
in signaling through the tyrosine kinases JAK1 and JAK3, and gene regulation through the 
transcription factor STAT5 (52, 54). The IL-2 receptor is expressed on both T-cells and NK-
cells.  
IL-2 has various effects in the T-cell and NK-cells compartments: it can promote the 
generation of effector T-cells. In addition, IL-2 is vital in the priming phase of an immune 
reaction for the development of long-lived memory T-cells in both the CD4+ and the CD8+ 
T-cell subsets (52, 55-57). IL-2 is also a central factor in the maintenance of regulatory T-
cells (51). In NK-cells, IL-2 up-regulates proliferation and effector functions, such as the 
induction of lymphokine-activated killer activity (58, 59). 
Recombinant human IL-2 has been used in clinical trials as a treatment against cancer with 
some success since the 1980s. Injection of IL-2 in patients with advanced stage metastatic 
malignant melanoma and renal cell carcinoma achieved complete remissions in 
approximately 7% of the patients, and partial responses in an additional 10% of the patients 
(51, 60). IL-2 has also been studied as a cancer treatment in combination with cellular 
therapies with, e. g. tumor-infiltrating lymphocytes T-cells with response rates around 20-
30% (61-63). 
I.1.iv.2 IL-7 
IL-7 is a homeostatic cytokine that, contradictory to being called an interleukin, is mainly 
produced by stromal cells (52, 64-66). IL-7 is necessary for the survival and development of 
T-cells and has an essential role in early T-cell development (67-71). It is produced by the 
epithelial cells in the thymus, and IL-7 signaling is critical for thymocyte development (72). 
The necessity of IL-7-mediated signaling in T-cell development is clearly illustrated by the 
fact that humans with defects in the IL-7 receptor develop a severe combined 
immunodeficiency characterized by a lack of T-cells, but the presence of NK-cells and B-
cells (2, 66, 73). In a study in mice where the expression levels of IL-7 could be controlled 
by a transgene, it was shown that there are distinct effects of different concentrations of IL-7 
upon T-cell development. Only low doses of IL-7 could support TCR-αβ T-cell development, 
while high doses effectively blocked development at an early intrathymic stage (66, 74). 
Circulating serum levels of IL-7 is normally low (0.3–8.4 pg/ml) (64), supporting T-cell 
development. However, this changes in lymphopenia when the levels can rise considerably as 
a response to low lymphocyte levels, as has been described in patients with HIV (75). 
Abnormally high levels can induce the development of lymphoma (76). Experimental data 
also suggests that different IL-7 levels influence the fate of mature T-cells. Low 
concentrations of IL-7 provide survival signals, while high concentrations can induce 
proliferation (69, 77). Different effects of IL-7 on naive CD4+ T-cells compared to CD4+ 
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memory T-cells have also been seen in vitro, with a higher proliferation rate in the memory 
compartment (78). The induced proliferation has also been seen to differ between CD4+ T-
cells and CD8+ T-cells: CD4+ T-cells proliferate significantly slower (79). In animal 
experiments of injection of IL-7, the increase of CD4+ T-cells was only four-fold as 
compared to the 14-fold increase in CD8+ T-cells (80). 
A central function of IL-7 is its pro-survival effects in memory T-cells. IL-7 is the main 
cytokine involved in the survival of CD4+ memory T-cells, and is thereby necessary for the 
maintenance of the CD4+ memory pool (81). Also, the homeostatic cytokines, including 
IL-7 and IL-15, have been shown to induce proliferation in CD4+ effector memory T-cells, 
and to a lesser extent also in CD4+ central memory T-cells (82). Umbilical cord blood 
CD4+ T-cells have a comparatively higher expression of the IL-7 receptor α-chain (CD127) 
than adult CD4+ T-cells, which might lead to increased sensitivity to IL-7 stimulation in 
this type of T-cells (83).   
IL-7 is also important to CD8+ memory T-cells (70, 84). The IL-7 receptor is essential in 
memory T-cell development (70, 85). Increased expression of the IL-7 receptor α-chain has 
been found to be a marker of memory development in CD8+ effector T-cells (86). 
However, the development of CD8+ memory T-cells has been shown to be possible to 
achieve in the absence of IL-7 (87). Thymic stromal lymphopoietin (TSLP), whose receptor 
consists of IL-7Rα and a β-chain specific for this cytokine, may be able to replace IL-7 in 
CD8+ T-cell memory development (88). IL-2 has been found to increase responsiveness to 
homeostatic proliferation induced by IL-7 and IL-15 in CD8+ memory T-cells (84), which 
might indicate that the addition of IL-7 could increase the efficiency of CD8+ T-cell 
proliferation in cell culture.  
IL-7 is a mediator of inflammation by inducing production of the pro-inflammatory 
cytokines IFN-γ, IL-2, tumor necrosis factor (TNF)-α and IL-4. This has been shown both 
in vitro and in animal models (89-91). IL-7 has also been shown to be associated with 
autoimmunity, supporting the hypothesized role of this cytokine in inflammatory responses. 
There is evidence of an association between polymorphisms in IL-7Rα and an increased 
risk of multiple autoimmune conditions, such as multiple sclerosis (92), rheumatoid 
arthritis (93), systemic lupus erythematosus (94), and inflammatory bowel disease (95), 
indicating that IL-7 is a link in a major pathway underlying these diseases (92, 96).  
I.2 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 
Allogeneic hematopoietic stem cell transplantation is currently the best available therapy for 
patients with a wide range of diseases such as hematologic malignancies, 
immunodeficiencies, inborn errors of metabolism and acquired bone marrow failure 
syndromes (4, 97). In many of these diseases, HSCT is the only potentially curative treatment 
available (97).  
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I.2.i A short history of HSCT  
The history of HSCT began more than 50 years ago with E. Donnall Thomas’s report of a 
new approach to cancer treatment based on radiation and chemotherapy followed by the 
intravenous infusion of bone marrow (98). An interest in the effects of irradiation had been 
awakened after World War II by the threat of atomic bombs. When Jacobson et al. found that 
mice could survive lethal irradiation if the spleen were protected by a lead foil (99), and 
Lorenz et al. described a similar protective effect of an infusion of spleen or marrow cells 
after irradiation (100), the foundation for what is today known as HSCT was lain (101). 
During the late 1940s and 1950s, intensive research was conducted into this new concept, but 
with little success. All recipients of bone marrow died of graft rejection, graft-versus-host 
disease (GVHD), or opportunistic infection. The breakthrough came in experiments 
conducted by Professor Thomas in an outbred canine model. He found that most dogs that 
received irradiation and infusion of littermate marrow had the same problems as humans, but 
that occasionally a dog became a healthy long-term survivor with marrow cells of donor 
origin. He and his colleagues then developed canine histocompatibility typing. By the mid-
1960s, they could show that most dogs given sufficient irradiation followed by grafts from 
dog leukocyte antigen-matched littermates survived long-term (102, 103). When 
histocompatibility testing in humans emerged, studies in humans was again initiated, 
culminating in the first successful transplantations in the 1970s (103). 
During the decades that followed, great advances in several aspects of the procedure have 
greatly improved the outcomes of HSCT recipients. These developments include better 
preparatory conditioning regimens and improved immunosuppressive and antimicrobial 
treatments (97, 101). The arrival of alternative donor sources has also increased the 
availability of HSCT (6, 7, 104-108). The number of transplants has increased continually, 
and currently over 50,000 HSCTs are performed annually worldwide (97, 109).  
I.2.ii Indications for HSCT  
The indications for HSCT are continually changing. Hematological malignancy is still the 
most common disease group in HSCT recipients, followed by primary immunodeficiency and 
other congenital hematological disorders. However, solid tumors are also HSCT indications 
in some transplant centers, and some autoimmune disorders have also been the cause of 
treatment with HSCT (110). Here follows a concise description of the more common HSCT 
indications: 
Of the hematological malignancies, acute and chronic myeloid leukemia (AML and CML, 
respectively), acute and chronic lymphatic leukemia (ALL and CLL, respectively), 
myelodysplastic syndrome (MDS), lymphomas and myeloproliferative diseases, are 
relatively common HSCT indications. Leukemia is a heterogeneous disease group defined by 
an infiltration of bone marrow, blood and organs by cancer cells of hematopoietic origin 
(111).  The prognosis and treatments alternatives vary between different leukemia types.  
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AML and ALL are fast-growing undifferentiated leukemias derived from the myeloid and 
lymphoid cell lineages, respectively (see Figure 2). AML arise from myeloid precursor cells 
of different maturation stages: approximately 20% of AML cases are found in cells that lack 
maturation from an early precursor stage, while others are found in later precursor stages such 
as monocytes, erythroid cells, or megakaryoblasts. ALL is derived from lymphoid precursors 
cells: B-lymphoblasts and T-lymphoblasts. The B-cell precursor types of ALL are most 
common. ALL is the most common malignancy in childhood (111). The different types of 
both ALL and AML differ significantly in many respects, including in prognosis. 
CML and CLL are malignant diseases of more mature cells of the myeloid and lymphatic 
cell lineages, respectively. (111). CML is characterized by clonal expansion of myeloid cells 
driven by a chromosomal fusion-derived gene, BCR-ABL (Philadelphia chromosome), and 
the progression is divided into different phases: chronic phase, accelerated phase and blast 
crisis, identified by the amount of malignant blast cells. The phase division is important for 
prognosis. In the case of CLL, the malignant cells originate from mature B-cells (111, 112). 
CLL is considered the leukemic manifestation of a type of lymphoma: small lymphocytic 
lymphoma (111). Lymphoma is a group of malignant diseases in lymphocytes, both T-cell 
and B-cell forms exist (111). Classical lymphomas are characterized by solid lymphoid 
tumors in different body sites. They are divided into Hodgkin’s lymphoma and non-Hodgkin 
lymphomas. The latter are further classified as indolent, aggressive and highly aggressive, 
according to the rate of growth. This classification is of great importance for the choice of 
treatment strategy. HSCT is a treatment option in several of the lymphoma types, in some as 
a primary treatment, in others after a relapse (110).  
MDS is a group of diseases caused by genetic aberrations in hematopoietic progenitor cells, 
classified as neoplasias (111). Myeloproliferative diseases is a collection of disorders 
characterized by overproduction of hematopoietic cells, e g thrombocytes or erythrocytes, 
and/or myelofibrosis, with defective bone marrow function and risk for leukemic 
transformation (111). 
The non-malignant diseases that are treated with HSCT include aplastic anemias, primary 
immunodeficiencies, metabolic disorders and hemoglobinopathies. Aplastic anemias can be 
divided into congenital and acquired types. Idiopathic severe Aplastic Anemia (SAA) is an 
acquired autoimmune condition where the bone marrow is destroyed by an immune reaction 
that seem to be driven by T-cells and cytokines such as IL-17, IFN-γ and TNF-α (113). 
Fanconi’s Anemia is an example of a congenital aplastic anemia and is caused by mutations 
in DNA damage repair genes. This disease is characterized by development of AML and 
solid tumors, bone marrow failure and developmental abnormalities (114). Primary immune 
deficiencies that require transplantation include severe combined immunodeficiency 
(SCID), where the patient lack B-cells and/or T-cells and/or NK-cells, chronic 
granulomatous disease (CGD) characterized by defective phagocytosis, and 
hemophagocytic lymphohistiocytosis (HLH) that is a condition with uncontrolled 
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inflammatory responses and the presence of abnormal phagocytes that engulf healthy bone 
marrow cells, causing cytopenia. Also, Whiskott-Aldrich syndrome, where the patients suffer 
from thrombocytopenia; IPEX, where the symptoms include immune-mediated cytopenia, 
and type 1 diabetes mellitus; and hyper-IgM syndrome, are considered HSCT indications (3). 
Among the metabolic diseases, Hurler’s syndrome is the most common HSCT indication. 
Hurler’s syndrome is also known as mucopolysaccharidosis type I, and is classified as a 
lysosomal storage disorder. Hemoglobinopathies, such as Thalassemia, are congenital 
defects in the hemoglobin genes, resulting in decreased functional hemoglobin levels, 
damage to the erythrocyte membrane and ineffective erythropoiesis (115). 
I.2.iii Sources for hematopoietic stem cell graft 
Hematopoietic stem cells (HSCs) are located in the bone marrow and can be harvested for 
HSCT grafts in different manners. The first approach used for obtaining HSC grafts was to 
harvest bone marrow manually from the posterior iliac crest with a bone marrow biopsy 
needle (22, 116). Additional methods for obtaining stem cell grafts have emerged during the 
50 years HSCTs have been performed (116). The most common graft in many centers today, 
especially for adult patients, is the peripheral blood stem cell graft. This type of HSC graft is 
harvested by apheresis after injections with granulocyte colony-stimulating factor (G-CSF) 
have induced the HSCs to migrate to the peripheral blood (116-118). Umbilical cord blood, 
harvested by collecting the blood in the umbilical cord and placenta after childbirth, has also 
more lately been discovered to be a rich source of HSCs that can be easily collected and 
cryopreserved as HSCT grafts (22, 116, 119). 
I.2.iv Donor selection  
The selection of a suitable donor is a crucial step in the transplantation process. Donor type is 
well-known to impact the outcome of HSCT (120). The selection of donors is made primarily 
on the basis of the human leukocyte antigens genes, striving for as complete a match between 
donor and recipients as possible. The HLA genes that are analyzed at the Karolinska 
University Hospital are HLA-A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1 -DQB1, -
DPA1, -DPB1 (121). The primary donor choice is an HLA-identical sibling, if possible 
avoiding a female donor to a male recipient, as this has been found to give the best outcome 
(22, 120). The chance of a 12/12 match is higher in siblings. A syngeneic twin, however, is 
not an optimal choice for patients with malignant disease, as this donor type is associated 
with an increased risk of relapse (122). At present, a matched unrelated donor from a donor 
registry is the second donor choice in many transplant centers, including Karolinska 
University hospital. This is also the recommended in the European Society for blood and 
Marrow transplant donor choice algorithm (22). Alternative donors sources, such as UCB and 
partially HLA-matched relatives are usually the 3rd choice of donor source. These alternative 
donor sources have more recently been introduced into HSCT. Both have gained ground over 
the last decade, and are now established in many centers. The results in transplantation with 
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UCB as a stem cell source, and with bone marrow or peripheral blood from haploidentical 
donors are comparable to those in transplantation with a matched related or unrelated donor 
(6, 107, 108, 123, 124). This thesis is focused on UCB, which has been the most commonly 
used 3rd choice graft at Karolinska University Hospital. Umbilical cord blood transplantation 
is described in more detail in chapter I.2.IX. 
I.2.v The transplantation procedure: preparations, conditioning treatment, 
post-transplantation neutropenia, engraftment and complications 
A schematic overview of the transplantation process is shown in Figure 6. 
The transplantation procedure is a complex process including several co-operating clinical 
specialties. First, the patient needs to be in a good clinical status to increase the chances of 
treatment success, and decrease the risk for complications. The patients with malignant 
disease are pre-treated with the aim of as extensive disease control as possible, to decrease the 
risk of relapse (120, 125). All patients are carefully checked for signs of infection and 
infection risks, as any current or latent infection will be probable to flare up when the control 
of the immune system is lifted after the transplantation. A previous study at CAST has shown 
that even a slightly increased level of C-reactive protein remaining after a recent infection is 
associated with a significant increase in transplant-related mortality (TRM) in patients 
receiving a reduced intensity conditioning (RIC) (126). This clearly underscores the 
importance of optimizing clinical infection risks before HSCT. 
In parallel to the procedures above, a donor is selected. The pre-transplant conditioning 
treatment is then initiated. This is a treatment that includes different types of chemotherapist 
drugs and sometimes also radiotherapy. The main functions of the conditioning treatment are 
to achieve disease control and to induce immunosuppression to prevent rejection. 
Conditioning treatment has also been thought to create necessary space in the bone marrow 
for the graft, but this is controversial (22).  
The conditioning regimens are either myeloablative (MACs), causing sufficient damage to 
the bone marrow calculated to make autologous hematopoietic recovery unlikely, or milder 
reduced-intensity conditionings. The MACs are usually cyclophosphamide combined with 
either busulphan or fractionated total body irradiation (TBI) (4). These are tough treatment 
regimes, limiting their applicability to younger patients in good clinical condition. The RICs 
used are usually combinations of fludarabine with a lower dose of cyclophosphamide or 
busulphan than in the MACs, or with treosulfan (4). Fludarabine and cyclophosphamide can 
also be used together with a low dose fractionated TBI (4). The choice of protocol is based on 
underlying disease, previous treatment, clinical status and age. Anti-thymocyte globulin 
(ATG) treatment is also added to the conditioning regimen in patients with malignant disease 
receiving a matched unrelated donor transplant or a UCBT, and in all patients with non-
malignant disease, to reduce the risk o rejection and to prevent GVHD (4). 
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The patients are also given immunosuppressive treatment to prevent GVHD. The most 
common regimes include calcineurin inhibitors, such as cyclosporine A or tacrolimus, in 
combination with a short course of methotrexate (127-129). The calcineurin inhibitors 
mediate an inhibition of T-cell function, and methotrexate is used to non-specifically deplete 
alloreactive cells that are activated soon after transplantation. More recent agents used for 
GVHD prophylaxis include sirolimus, which inhibits T-cell function by blocking activation 
of mammalian Target of Rapamycin (130), and mycophenolate mofetil, which causes 
blockade of T- and B-cell function (22). 
The graft is infused after the conditioning treatment is concluded. Then a period of 
neutropenia follows. The patients either stay in the hospital ward, isolated during daytime, or 
in home care with special regulations due to their extreme susceptibility to infection during 
this period (131). During the neutropenia, the damage caused by the conditioning regimen 
cannot heal properly. This results in mucositis, a painful condition with wounds and blisters 
in mouth and throat, and diarrhea caused by damage to the mucosa of the gastrointestinal 
tract. Mucositis resolves at engrafted, when production of neutrophils is resumed.  
Engraftment, which is when leukocytes become measurable in peripheral blood after HSCT, 
is usually a sign of the transplanted stem cells being established successfully in the host. 
However, in a small percentage of HSCT recipients the emerging cells are autologous and 
signal graft rejection. Engraftment is defined as a blood neutrophil count of >0.5×109/L, and 
a platelet count above 30×109/L. If no engraftment is detected, the graft has failed to be 
established in the bone marrow. Graft failure is defined as no reconstitution of hematopoiesis 
4'
Condi2oning'
Transplanta2on'
Cytosta2c'drugs,'
radiotherapy'
Reduces'pa2ent’s'own'
bone'marrow'
Infusion'of'stem'
cells' Neutropenia'
High'risk'of'infec2on'
An2microbial'prophylaxis'
Pa2ents'are'isolated'
Take'
Prophylaxis'
Hematopoie2c'stem'
cell'transplanta2on'
Figure 6. The transplantation process. 
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after HSCT. Rejection, where the host immune system manages to eradicate the transplanted 
cells, is defined as either no detection of donor cells after HSCT or complete loss of donor 
cells after initial engraftment. These definitions were used in scientific paper I, and are 
adapted from Nordlander et al (132). 
 
HSCT is a difficult treatment, associated with severe complications and even a degree of 
mortality. The most common categories of complications are infections, GVHD and relapse.  
Cancer relapse remains the major cause of failure in HSCT recipients with malignant diseases 
(4, 133), despite the strong immune-mediated graft vs. tumor effect (GVT) (5). Relapse is 
also one of the few aspects of HSCT that has not improved during the last decades. This is 
still an area where additional and improved methods for early diagnosis and treatment are 
urgently needed. Infectious complications and GVHD will be described more in detail below. 
An overview of the complications is found in Figure 7.  
I.2.vi Infectious complications after hematopoietic stem cell transplantation 
The infectious complications can be divided based on the causative pathogens: bacterial, 
fungal and viral infections. 
Bacterial infections are common in the neutropenic period before engraftment. The most 
common path of infection is the translocation into the blood of bacteria from the normal 
endogenous flora in the gastrointestinal tract, mouth, throat and skin. Another common path 
of infections are via intravascular devices, such as central intravenous catheters. Streptococci, 
Figure 7. An overview of the common complications after HSCT 
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Staphylococci, Enterococci and E. coli are the most common types of bacteria in neutropenia 
(22, 134). Later after the transplantation, there is an increased rate of infections with 
encapsulated bacteria, like Streptococcus pneumonia and Haemophilus influenza. This type 
of infection primarily affects patients with chronic GVHD, patients that have undergone 
splenectomy and patients with low blood antibody levels (22).  
Fungal infections after HSCT are usually caused either by yeasts, mainly candida, or by 
molds, most commonly aspergillus. Candida infections dominate in the early parts of the 
transplant process in consequence of neutropenia and damaged mucosal surfaces. Patients 
receive prophylaxis against Candida infections, and invasive infections are rare. Mold 
infections, as is illustrated in Figure 5, become the more frequent of the fungal infections 
after the first month post-transplantation. Mold infection is a relatively common cause of 
severe infection and infection-related death after HSCT: 5-15% of HSCT recipients develop a 
mold infection with apergillus, and 60% of these patients die from the infection (135). Mold 
infections are most commonly contracted by inhalation of air-borne spores, which makes 
prevention difficult (22). 
Virus infections after HSCT are commonly caused by herpes viruses. The most common of 
those is cytomegalovirus (CMV). A large proportion of the population is infected with CMV 
in childhood. The virus becomes latent after the primary infection, and is carried by the 
infected individual without causing symptoms. Symptomatic reactivation of CMV is only 
seen in immunosuppressed individuals such as transplant recipients (22). CMV can cause 
disease in many organs, such as the lungs, the gastrointestinal tract, the meninges and the 
eyes of an immunosuppressed host, and was one of the more common causes of transplant-
related death before the advent of effective treatments (136). Quantitative PCR-based 
monitoring of CMV reactivation is recommended in all HSCT recipients (136). 
Another herpes virus that can cause severe disease in immunosuppressed individuals is 
Epstein-Barr virus (EBV. Primary EBV infection is common in children and young adults, 
and causes mononucleosis. Similarly to CMV, EBV is carried in a latent state after the 
primary infection. EBV reactivation in HSCT recipients it can cause a life-threatening 
complication called post-transplantation lymphoproliferative disease (PTLD). This is an 
EBV-driven uncontrolled proliferation of B-cells similar to lymphoma. Monitoring of EBV 
reactivation using quantitative PCR is recommended in patients with high risk for this 
complication. The risk factors for PTLD that have been identified are: unrelated and/or 
mismatched donor; use of T-cell depletion, treatment with ATG; EBV serology mismatch 
between the donor and the recipient; primary EBV infection, and splenectomy. 
Varicella zoster virus (VZV) reactivation is common after HSCT, with a cumulative 
incidence of approximately 20% in patients at our center (137). VZV is also a member of the 
herpes virus family, and the cause of chicken pox and shingles. Chicken pox is very common 
in childhood and represents the primary VZV infection, after which the virus becomes latent. 
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A later reactivation of VZV results in shingles. Complications of VZV reactivation in HCT 
recipients include postherpetic neuralgia, disseminated infection, and occasionally even death 
(137). 
Adenovirus is a common virus that mainly affects children, causing respiratory symptoms 
and gastroenteritis. In HSCT recipients, adenovirus can cause severe infections with disease 
manifestations such as hepatitis, pneumonitis, encephalitis, colitis and hemorrhagic cystitis, 
and with considerable morbidity and mortality (138, 139). In a proportion of the transplanted 
patients, adenovirus appears concomitantly to other infections, such as CMV, EBV and 
invasive fungal infections, which is associated with poor prognosis (138).  
Other important viruses that pose a danger to transplant recipient are human herpes virus 6, 
which can cause encephalitis in immunosuppressed individuals (22) and Parvovirus B19, that 
can cause myelosuppression (140, 141). Common infections like influenza and calici virus 
infection, can also infect transplanted patients, and in them cause more severe symptoms and 
longer infection duration (142).  
I.2.vii Graft-versus-host disease and graft-versus-tumor effects 
One major mechanism in HSCT that mediates the cure of hematological malignancy is the 
immunologically mediated eradication of the remaining malignant cells by the donor immune 
system. The immunogenicity in the recipient’s cancer cells that permits the donor’s immune 
system to identify and destroy them is thought to be induced by the genetic differences 
between donor and recipient outside the analyzed HLA genes. Evidence of a donor immune-
mediated mechanism behind the GVT effect came in the late 1970s, when higher frequencies 
of relapse after transplantation with syngeneic HSCT than allogeneic HSCT were reported 
(143). Another milestone report from the early 1990s showed that the incidence of relapse 
was increased in HSCT with T-cell depleted grafts compared to with T-cell replete grafts. 
The increased risk of relapse also corresponded to a decreased risk of GVHD (122). The 
same study also found an increased rate of relapse in patients that had received syngeneic 
grafts from an identical twin, supporting the theory of an immune-mediated GVT effect 
driven by genetic differences. When donor lymphocyte infusion (DLI), a type of treatment 
where bulk donor lymphocytes are infused after transplantation, was shown to induce 
remission in relapsed malignancies post-HSCT, this formed additional support of an immune-
mediated GVT effect (144). The GVT effect is thought to be mainly produced by T-cells (5, 
145-147). T-cells could mediate GVT through several mechanisms, including cytokine-
mediated effects and cytolytic activity. Cytolytic activity can be mediated either through Fas 
receptor−Fas ligand-mediated apoptosis or by perforin/granzyme degranulation. CD4+ T-
cells appear to predominantly induce apoptosis by Fas receptor−Fas-ligand interaction, while 
CD8+ T-cells seem to mediate GVT effects mainly by perforin degranulation (146). Data 
supporting a central role for CD4+ T-cells for the GVT effect in clinical HSCT has been 
published (148). NK-cells, and other cell subsets, have also been implicated as effectors of 
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the GVT effect (149). Intense research efforts have been directed against identifying the 
antigens that drive the immune reaction in GVT, resulting in a growing list of potential 
candidates. An association between GVHD and GVT has been found in a large number of 
studies over the decades, suggesting that the GVT effect is closely allied to GVHD and that 
GVT responses target antigens in a non-tumor-specific manner (122, 150). 
GVHD is mediated by a host immune reaction directed towards the tissues of the recipients 
and can be considered the reverse side of the beneficial alloreactivity of the GVT effect. 
There is an acute and a chronic form of GVHD that differ in pathogenesis, symptoms and 
time of debut.  
Acute GVHD is usually developed during the first months after transplantation, and most 
commonly affects the liver, the gastrointerstinal tract, and the skin. The symptoms can be so 
severe that they directly, or indirectly by subsequent infection, lead to death. The pathology 
has been attributed to a process that starts with the tissue damage caused by the conditioning 
regimen. This leads to activation of host antigen-presenting cells and donor T-cells and 
finally to inflammation and tissue necrosis associated with inflammatory cytokines such as 
IL-1 and TNF-α (22). Risk factors for GVHD include HLA mismatch between donor and 
recipient, and female-donor-to-male-recipient HSCT (22). The latter risk is believed to be due 
to the fact that the new host immune system will not have encountered Y-chromosome gene 
products (151).  
Chronic GVHD usually arise more than three months after HSCT. It is caused, like acute 
GVHD, by host alloreactivity directed towards recipient tissues, butchronic GVHD is also 
considered a disease of immune dysregulation with, and shares features with autoimmune 
diseases such as Sjögren’s syndrome, scleroderma, primary biliary cirrhosis and 
immuncytopenias (22). The deails of the pathogenesis is poorly understood. T-cells and B-
cells are believed to play central roles (22, 152). There is an increased rate of mortality in 
patients with chronic GVHD as well as in acute GVHD, but mainly indirectly, as a result of 
an increased susceptibility to infection. GVHD treatment is based on immunosuppressive 
therapy, and the treatment time of chronic GVHD is often long. The immunosuppressive 
treatment together with the immunosuppressive effects of the chronic GVHD in itself lead to 
a dramatically increased risk of infection (22). Some major risk factors for chronic GVHD are 
prior acute GVHD, HLA mismatch, older patient age, previous splenectomy and female-
donor-to-male-recipient transplantation (22, 153, 154). 
Chronic GVHD is the form of GVHD most firmly associated with GVT effects, observed in 
the improved long-term survival in patients that do develop this complication. However, 
extensive chronic GVHD causes severe morbidity and mortality, like the autoimmune 
diseases that it shares characteristics with. The chances of achieving GVT effect is always 
balanced by the risk of inducing GVHD in HSCT, and immunosuppressive treatment is at 
present the only clumsy tool available for manipulating this precarious balance with. 
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I.2.viii Monitoring of patients after HSCT 
Close monitoring of patients after HSCT is of paramount importance for early detection of 
complications. The monitoring methods available are mainly based on the analysis of 
peripheral blood samples and bone marrow biopsies. These are assessed for the ratio of 
donor- and recipient-derived cells (chimerism) and for molecular, cytogenetic or 
morphological signs of relapse (in patients with malignant disease), signs of abnormalities in 
the hematopoietic cells in the bone marrow indicating suppression of the graft, signs of 
organ-specific GVHD and signs of infection. The early detection of these complications 
enables early treatment, which is associated with better outcome in most of the complications 
after an HSCT. 
Chimerism analysis is a genetic assay used for determination of the percentage of recipient 
and donor origin in hematopoietic cells. This assay allows the assessment of immunological 
interactions between the donor and recipient immune systems. Chimerism analysis enables 
assessment of successful engraftment, and can also provide the physician with early 
indications of graft rejection (22, 155-158) and impending relapse in patients with malignant 
disease (159, 160). 
Chimerism analysis was performed on samples from blood and bone marrow after 
transplantation in all the UCBT recipients to monitor engraftment and to facilitate early 
detection of relapse. Analysis was performed regularly at short intervals initially, up to 3 
months, then at 6, 9, 12, 18, and 24 months, and thereafter annually. At Karolinska University 
Hospital, chimerism analysis is performed to evaluate donor and recipient chimerism in 
CD3+, CD19+, and CD33+ cells enriched from peripheral blood using immunomagnetic 
beads (Dynal, Oslo, Norway) (160). Two methods of analysis have been used in this thesis 
for chimerism analysis. One method used was based on polymerase chain reaction (PCR) 
amplification of variable numbers of tandem repeats, using minisatellites (160), while the 
other comprised a real-time PCR analysis based on single nucleotide polymorphism (7).  
Complete donor chimerism (DC) was defined as >95% donor cells. Mixed chimerism (MC) 
was defined as <95% but >5% donor cells. Mixed donor-donor chimerism (MDC) was 
defined as a DC after double cord blood transplantation (DCBT) with no remaining recipient 
cells, but with a proportion of both the donors present. 
Bone marrow biopsies were performed for histopathology analysis of relapse of malignant 
disease, and to a lesser extent to assess the engraftment of donor hematopoiesis. The bone 
marrow samples were also sent for cytogenetic analysis and flow cytometry to assess return 
or persistence of malignant cells. This assessment is called minimal residual disease (MRD). 
I.2.ix Umbilical cord blood transplantation (UCBT) 
Umbilical cord blood has emerged as a valid alternative graft source in allogeneic HSCT in 
the 25 years that have passed since the first successful UCBT (104, 161). Grafts are obtained 
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by collecting the blood from the umbilical cord and placenta after childbirth. The collected 
blood is cryopreserved without any previous cell separation, to preserve as many cells as 
possible, in appointed cord blood banks (104). Transplantation with UCB as a graft source 
leads to successful hematopoietic engraftment and yields clinical results comparable to those 
seen in HSCT with other stem cell sources (7, 104, 106, 124). Interest in this mode of HSCT 
has increased during the last decades, and UCBT has been implemented internationally. The 
unique advantages with UCB as a graft source are appealing: the most striking merit of this 
graft type is the permissibility for HLA-mismatch, which is not seen with adult graft sources. 
This permissibility greatly increases the chance of finding a donor for patients lacking an 
HLA-matched related or unrelated donor (9, 104). Other advantages with UCB include rapid 
availability of the frozen grafts from umbilical cord blood banks and comparatively risk-free 
collection of grafts with regard to the donor (9, 104). There are, however, also drawbacks to 
UCB as a graft source: UCBT is associated with delayed engraftment and poor immune 
reconstitution, especially during the initial months after transplantation. During this period, 
UCBT recipients have an increased risk for severe infections compared to recipients of 
transplantations with other graft sources. The grafts are comparatively expensive to obtain, 
and the costliness of the UCBT procedure is also increased by the complicated post-transplant 
period. The unavailability of donor cells for post-transplant therapy such as DLI and stem cell 
boosters is another major drawback (11, 104, 162) 
I.3 IMMUNOTHERAPY 
I.3.i Anti-cancer effects of the immune system 
The concept of an immune surveillance function where the immune system locates and 
eradicates cancer cells, have been discussed for more than 50 years, and supportive evidence 
have been difficult to obtain. A recent review, however, has stated several arguments in 
support of the existence of such a function. One of the arguments was that both animals and 
humans with immunodeficiency have increased risk of cancer development. Mice that lack 
adaptive immune cells and mice that lack the ability to produce IFN-γ have an increased risk 
for both spontaneous and carcinogen-induced tumor development (163, 164). Humans with 
primary immunodeficiency and HIV have also been reported to have increased incidences of 
cancer (17, 165, 166). Organ transplant recipients, who are treated with immunosuppressive 
drugs, are also more prone to cancer development (17, 167). The quantity and quality of the 
immune cell infiltrate found in tumors has been shown to be an independent prognostic factor 
for outcome (17, 168-174). Cancer cells also selectively accumulate mutations to avoid 
infiltration of immune cells and a consequent immune-mediated destruction of malignant 
cells (17, 175, 176). Lymphocytes bearing the NK-cell receptor NKG2D receptor can find 
and eliminate premalignant cells (17, 177). Collectively, this indicates that the immune 
system plays a role in preventing cancers from developing. To harness this anti-cancer effect 
and focus it in engineered therapies are the main goals in immunotherapy. 
 34 
I.3.ii Approaches in immunotherapy 
Harnessing of the anti-cancer capacity of the immune system for cancer treatment has been 
attempted with promising results. In essence, cancer immunotherapy can be defined as 
manipulations of the immune system to achieve an increased activity toward tumor cells. 
Current approaches in immunotherapy are directed toward a wide range of different 
mechanisms of the immune system. Studies focused on the inhibition of T-cell development 
checkpoint molecules like cytotoxic T-lymphocyte-associated protein (CTLA)-4, 
programmed cell death protein (PD)-1, or PD-ligand 1 have produced interesting clinical and 
pre-clinical data (178-182). Intravenous interleukin treatment, as discussed in chapter 
I.1.IV.1, has been tried with both IL-2 and IL-7, among other substances, with promising 
results. Treatment with IL-2 has been found to induce durable cancer regression in a small 
portion of patients with advanced malignant melanoma and renal cell cancers (60). Treatment 
using cultured tumor-infiltrating lymphocytes, with and without parallel administration of 
intravenous IL-2, has also induced tumor regression in patients with very advanced cancers 
(61, 62). Treatment with IL-7 in patients with refractory malignancies resulted in increased T-
cell levels, and possible anti-tumor effects in one out of 16 patients (183). Bi-specific T-cell 
and NK-cell engager antibodies (BiTEs and BiKEs) are other relatively new approaches in 
immunotherapy. These antibodies allow the in vitro coupling of effector and target cells, 
activating the effector cells while simultaneously marking out the target cells for destruction 
(184, 185). Adoptive cell therapy (ACT) is another branch of immunotherapy and comprises 
infusion of different kinds of in vitro manipulated cells. This includes treatment with T-cells 
transfected with tailored chimeric antigen receptors (CARs) directed towards cancer targets, 
such as CD19, a treatment modality that have lately astounded the research community 
(186, 187). Cultured tumor-infiltrating lymphocytes (TILs) (184, 185, 188) is another 
promising type of ACT. Jointly these approaches underscore the versatility and 
unprecedented possibilities of the immunotherapy field. Donor lymphocyte infusions is 
currently the most common ACT in the HSCT setting. The major indication for DLI 
treatment is relapse of hematological malignancy. The benefits of DLI are most pronounced 
in patients with relapsed CML and low-grade lymphoid malignancies (144, 189). DLI 
treatment has also been shown to be of benefit against relapse after HSCT in other 
hematological malignancies, especially if the treatment was initiated due to molecular signs 
of relapse rather than overt hematological relapse (144, 190, 191). Whether the results 
warrant the toxicity (mainly GVHD) in acute leukemia and MDS is arguable (189, 192-
195). Virus-specific T-cells from a haploidentical third party donor for treatment of post-
transplantation viral complications have also generated good clinical results (196, 197). 
I.3.iii Immunotherapy in UCBT 
One considerable drawback to UCB as a graft source is the lack of conventional DLI, 
which is a consequence of the low cell doses of UCB grafts and ethical considerations that 
excludes approaching the donor after the initial donation (10, 11, 198-200). As the number 
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of performed UCBTs continues to grow, it becomes increasingly urgent to find alternatives 
to DLI for UCBT recipients. Several approaches have been tried to develop alternatives to 
conventional DLI in the UCBT setting (10, 11, 198-200). One of those is the non-specific 
culture of T-cells from an aliquot of the original UCB graft (10, 11, 198, 200). This strategy 
has the advantage of yielding a product that shares characteristics with conventional DLI. 
To produce a product with non-selected, polyclonal T-cells is a logical step as antigens that 
drive the GVT effect are unknown. There is a high probability of producing cultured T-cell 
populations that contain alloreactive T-cell when all T-cell clones are equally stimulated. 
Other approaches that have been tried include bulk CD4+ T-cells (201) and expanded T-
cells with single or multiple pre-determined specificities (199, 202). Some of the 
engineered products described in the literature have combined specificities for several 
viruses and known leukemic antigens in the same cell population (199). 
The culture protocols used in T-cell based ACTs usually rely on expansion induced by 
artificial TCR/co-receptor stimulation combined with further activation and modulation by 
cytokines (10, 198, 200). The choice of cytokines is instrumental in creating a cell product 
well suited to its purpose. In this thesis, focus has been on the cytokines IL-2 and IL-7. As 
described above, these cytokines have several characteristics that single them out as 
potential candidates for effective cell culture in the UCBT setting. This will be discussed 
further in the results section. 
The developmental and functional phenotype of adoptively infused T-cells has been found 
to have a considerable impact of the efficacy and longevity of the treatment. Preclinical 
ACT studies of in mice and non-human primates have shown that central memory T-cells 
persist longer in vivo, and have greater antitumor efficacy, than effector memory T-cells 
(203-205). Also, a study performed in mice has indicated that a Th17-polarised CD4+ T-
cell population is the most effective ACT in malignant melanoma (206). Another candidate 
for ACT is a relatively recently described T-cell memory phenotype, termed memory stem 
T-cells. They are described to have a distinct phenotype, are thought to be long-lived, have 
the ability to self-renew, and to have a high degree of plasticity of differentiation, e. g. into 
potent effectors (41, 207, 208). Other in vitro studies has shown that effector memory T-
cells have superior potential to acquire and exert cytolytic functions and cytokine 
production in vitro (209, 210). These partly conflicting reports indicate that there is more to 
learn before the optimal T-cell phenotype or ACT can be determined. They also show that 
the memory status of the cultured cells is important for the clinical outcome of the 
treatment. However, products with a high proportion of central memory T-cells, or possibly 
memory stem T-cells, could prove to be most long-lived, and thereby possible also most 
effective. Different strategies to induce the requisite phenotype will then need to be 
developed. Strategies that have been suggested include aiming for a short culture time, 
keeping cytokine levels as low as effectively possible and attempting artificial enforcement 
of a more naïve phenotype by induction of CD28 or telomerase expression (211).  
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I.4 AN INTRODUCTION TO THE METHODS USED IN THE THESIS WORK 
I.4.i Flow cytometry 
Flow cytometry was used in scientific papers III and IV of this thesis, and is a method for 
analyzing the properties of a particle, in the present case, a cell. The great advantage of this 
method is that it allows the assessment of properties of a single cell in a sample. Flow 
cytometry can be used to determine the presence and relative amount of molecules on the 
extracellular surface of the cell, or inside the cell, in the cytoplasm and the cell nucleus (212). 
This provides information on the cellular phenotype, or characteristics, and can also 
determine if a cell is alive, apoptotic or dead. Analysis of cell cycle characteristics can also be 
performed. The method allows the user to categorize cells into different subsets, which can 
yield information regarding what type of cells there are in the sample, if they are alive, if they 
are producing and secreting different signaling molecules, and if they have effector 
substances stored in granules or expressed on their surface.  
Flow cytometric analysis is based on the use of marker-specific antibodies coupled to 
fluorochromes, which allows the detection of the targeted marker in the flow cytometer. The 
flourochrome is essentially a type of dye, a molecule that accepts light at a certain 
wavelength; and then emits the energy at another wavelength. This process of emission is 
known as fluorescence (212). 
Fluorescence is utilized in flow cytometry by letting a laser beam hit the flourochrome in a 
controlled and predictable fashion and then detecting the emitted fluorescence. The laser 
beam is scattered at a forward and at a ninety degrees angle to allow assessment of the basic 
cellular characteristics, such as size, nuclear complexity and cytoplasmic granularity (212). 
During data aquisition the cells are passed through the laser beam in a thin stream forcing the 
cells into a single file. This single-cell stream is obtained by hydrodynamic focusing, where 
the sample stream is injected into a faster flowing stream of sheath fluid, most often 
phosphate-buffered saline (212). This enables analysis of a single cell at a time. The number 
of channels for fluorescence detection of the flow cytometer used, which can vary from 3 or 4 
up to 18 (213, 214), and determines the complexity of single cell information that is possible 
to analyze in a single sample.  
The analyses of the present study have been focused on the study of mainly T-cells, but also 
to a lesser extent NK-cells and B-cells. Phenotype, cytokine production, degranulation and 
viability have been studied with this method. The markers used and their properties are found 
in Table 1. 
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Table 1   
Marker Cell type Characteristics and area of use 
CD3 T-cells Expressed by all T-cells, used for identification 
CD4 T-helper cells Co-receptor expressed on all T-helper cells 
CD8 Cytotoxic T-
cells 
Co-receptor expressed on all cytotoxic T-cells 
CD14 Monocytes Expressed on monocytes and macrophages 
CD16 NK-cells NK-cell marker 
CD19 B-cells Expressed by B-cells, used for their identification 
CD25 T-cells IL-2 receptor α-chain. Expressed on T-regs. 
CD28 T-cells Co-activating receptor on T-cells, mostly on naive 
CD45RA T-cells Found on naive T-cells  
CD45RO T-cells Marker of memory identification, see definition 
CD56 NK-cells Expressed by NK-cells, used for identification 
CD69 T-cells Early activation marker in T-cells 
CD85j NK-cells Inhibitory NK-cell receptor for MHC class I 
CD94 NK-cells NK-cell receptor, expressed by some T-cells 
CD95 T-cells Receptor for induction of apoptosis 
CD107a T-cells Marker of degranulation 
CCR7 T-cells Marker of memory identification, see definition 
IL-2 T-cells Cytokine, T-cell activation 
IL-10 T-cells Anti-inflammatory cytokine 
IL-17a T-cells Effector cytokine of the CD4+ T helper 17 subset 
IFN-γ T-cells Cytokine produced by T- and NK-cells. Activates macrophages. 
TNF-α T-cells Pro-inflammatory cytokine 
TCR αβ T-cells TCR made up by one α-chain and one β-chain 
TCR γδ T-cells TCR made up by one γ-chain and one δ-chain 
TCR Vγ9 T-cells One of the γ-chain subtypes of the TCR γδ 
TCR Vβ 1-3, 5, 7, 8, 11-14, 16, 
17, 20, 22 
 
T-cells TCR β-chain subtypes, used for the assessment of polyclonality  
HLA class I A3 All nucleated 
cells 
MHC class I of type A3, here used for separation of two donors in 
a DCBT recipient 
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I.4.ii T-cell stimulation assay 
The T-cell stimulation assay was used to analyze T-cell function in scientific papers III and 
IV. Peripheral blood mononuclear cells from blood samples and thawed cultured UCB T-
cells, in scientific paper III and IV, respectively, were re-suspended in complete medium with 
substances causing non-specific T-cell activation to assess the T-cells ability to respond to 
mitogens. The substances used were ionomycin calcium salt and phorbol 12-myristate 13-
acetate (PMA). To assess the cytokine production upon activation, cellular cytokine secretion 
was inhibited by adding GolgiStop® or Brefeldin A, in scientific paper III and IV, 
respectively. Cells were subsequently incubated at 37° C with 5% CO2 for 16 hours. The cells 
were then stained for the markers of interest and analyzed by flow cytometry.  
I.4.iii NK-cell stimulation assay 
NK-cell function was analyzed in paper III. Peripheral blood mononuclear cells from blood 
samples were resuspended in medium with GolgiStop® and incubated with PMA, or K562 
cells at a ratio of 1:1, for 4 h at 37°C in 5% CO2. This was done to enable assessment of the 
NK-cells capability to respond to appropriate stimulation. K562 is a myeloid leukemia cell 
line of the erythroleukemia type, derived from a 53 year old female CML patient in blast 
crisis (215). K562 cells are easily killed by natural killer cells (216) as they lack the MHC 
complex required to inhibit NK-cell activity (217). After incubation, cells were harvested and 
stained for flow cytometric analysis.  
I.4.iv Luminex 
Luminex analysis was used to determine the cytokine content of culture supernatants at the 
end of UCB T-cell culture in scientific paper IV. At the end of culture, concomitant with 
cryopreservation of the cultured T-cells, supernatant was collected and analyzed for: eotaxin, 
granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating 
factor (GM-CSF), IFN-α2, IFN-γ, IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-
10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IFN-γ-inducible protein -10, monocyte 
chemotactic protein-1, macrophage inflammatory protein (MIP)-1a, MIP-1b, tumor necrosis 
factor (TNF)-a, and TNF-b with the Milliplex Map Human cytokine/chemokine—premixed 
26 Plex from Millipore. The Luminex analysis is based on beads with defined spectral 
properties that are conjugated to protein-specific capture antibodies. Addition of the beads to 
samples results in the target protein binding to the capture antibodies. Then additional 
antibodies bearing a fluorochrome are added before the sample is analyzed with a Luminex® 
detection system. By monitoring the spectral properties of the beads and the amount of 
fluorescence, the concentration of one or more proteins can be determined.  
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I.4.v UCB T-cell culture and obtaining samples for culture 
For the study presented in scientific paper V on the culture of UCB T-cells for potential 
clinical use as ACT, an aliquot was obtained from the UCB grafts thawed for transplantation 
at CAST. Five percent of the total volume of every UCB graft has been collected since 2007. 
In total, cultures have been performed for 40 CB units (31 patients, 33 UCBTs). The 
expansions were given consecutive numbers as they were collected. The median total 
nucleated cell count in the aliquot was 60.5 million (range 20-154).  
Non-clinical units were used for the studies of the effects of adding IL-7 to the culture 
protocol that are presented in scientific paper IV. The UCB was then obtained from healthy 
volunteers undergoing cesarean section at the maternity ward at Karolinska University 
Hospital Huddinge. All donors provided informed consent before donation as approved by 
the ethics committee at the Karolinska Institute (DNR 2007/4:10). Mononuclear UCB cells 
For the cultures, either the aliquot of the clinical UCB graft was taken at thawing, or non-
clinical cryopreserved mononuclear UCB cells were thawed, according to the protocols in 
scientific paper IV and V, respectively. T-cells were positively selected with anti-
CD3+/CD28+-covered paramagnetic beads. The beads also function as artificial APCs and 
mediate an activation of the T-cells. The selected T-cells were cultured at a concentration of 3 
× 105 cells/mL in complete medium1640 RPMI with 10% pooled human AB-serum, 100 
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Figure 8. The UCB T-cell culture process. 
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IU/mL penicillin G, 100 mg/mL streptomycin, 0.25 mg/mL amphotericin B and 2mM L-
glutamine. Recombinant IL-2 was added in varying concentrations (0–600 IU/mL) and IL-7 
(20ng/mL) was added according to protocols in scientific papers IV and V (Table 2). Cell 
culture was performed at 37°C at 5% CO2. Viable cells were counted regularly and 
resuspended to maintain the concentration of living T-cells at 3 × 105 cells/ml. At the end of 
culture, T-cells were harvested and remaining beads were removed by magnetic separation. 
Expanded UCB T-cells were then cryopreserved. The culture process is illustrated in Figure 
8. 
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II. AIMS 
 
The aims of this thesis work were to achieve a greater understanding of the UCBT process, 
and to improve the treatment opportunities available to recipients of UCB grafts. This patient 
group lacks the possibility of treatment with additional donor cell after the transplantation, 
which is available for recipients of grafts from adult stem cell sources. This lack of donor-
derived cellular therapies results in a severely limited treatment arsenal against relapse of 
hematological malignancies and graft failure in UCBT recipients. This work was conceived 
in response to the urgent need for novel treatment approaches in UCBT. We aimed to: 
1. Evaluate clinical outcome and risk factors for complications after umbilical cord 
blood transplantation, and to analyze the development of donor chimerism in 
umbilical cord blood recipients. 
2. Develop clinically safe expansion protocols of donor T-cells from umbilical cord 
blood, and to characterize them in order to treat rejection or relapse of the 
underlying disease after umbilical cord blood transplantation. Also, we aimed to 
assess of the safety and outcome of treatment with the cultured cells. 
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III. RESULTS AND DISCUSSION 
The five articles presented in this thesis were performed with the intention of reaching a 
greater understanding of the UCBT process, and of developing novel adoptive cell therapies 
for patients that have undergone UCBT. 
The first aim was to comprehensively study the results of UCBTs performed at our clinic. 
This type of retrospective single-center analysis is of significant value, and not only for 
quality control purposes. The compiled single-center data, when compared to international 
results, can help to identify factors that can be improved in local medical practice. The 
elucidation of local factors influencing treatment outcome is another important point in favor 
of retrospective single-center studies. Factors such as climate parameters, affecting both the 
panorama of infectious pathogens (218), and patients’ behavior with regard to e. g. exercise 
and sun exposure, can necessitate adaptations in medical practice. Differences in diagnostic 
procedures and availability of specialist consultants can also be of importance for the patient 
outcome. These factors cannot always be predicted or extrapolated from international 
experience. Thus, analysis of single-center clinical results can provide guidance in clinical 
choices and pinpoint how local factors interact to create unexpected effects. However, the 
comparative smallness of our center necessitates longer data collection times, which 
complicates the analysis by adding time-dependent issues such as changed medical practices 
and variable follow up time. The small number of annual UCBTs also resulted in inclusion of 
heterogeneous patient materials in the studies. 
The results of scientific papers I and II have been useful in guiding decisions about the 
transplant procedure at CAST. The results of scientific paper I led to a discontinuation of the 
use of mesenchymal stem cells (MSCs) as engraftment support in UCBT, and the dosage of 
ATG has been lowered for recipients of DCBT as a result of the findings in scientific paper 
II.  
A large part of the work presented in the first three scientific papers is focused on chimerism 
development after UCBT. Our center has a tradition of frequent chimerism analysis after 
HSCT, in three or more cell lineages, creating a unique foundation for comprehensive 
chimerism analysis. We wanted to exploit this by performing in-depth studies of the 
dynamics of chimerism development in UCBT recipients. In scientific paper I, chimerism 
development was analyzed in all the patients that had been transplanted with UCB at CAST. 
Scientific paper II focused on chimerism development in patients that had undergone DCBT. 
In this study we described two patients with long-term mixed donor-donor chimerism (MDC) 
after DCBT with two unrelated and partly HLA-mismatched UCB grafts, a very unusual 
occurrence. The co-existence of two transplanted immune systems of unrelated origin in the 
same host is fascinating. We wanted to further explore and characterize this interesting 
chimerism state, which led to the performance of the study presented in scientific paper III. 
We here studied whether the immune phenotype and functionality differed in these two 
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patients compared to UCBT recipients with only one donor system, and how the two 
transplanted units differed from each other. 
The second aim was to develop alternative adoptive cell therapies for the UCBT setting. The 
research group in which this thesis was performed has for several years been researching 
alternatives to conventional DLI for UCBT recipients, and some of this work was published 
prior to the present project (11). The chosen strategy was to culture UCB T-cells from an 
aliquot of the UCB graft, using CD3/CD28-stimulation with antibody-covered paramagnetic 
beads and IL-2. The work presented in scientific paper IV was performed in attempting to 
optimize the protocol by adding IL-7 to IL-2 in the culture medium. We also wanted to study 
the biological effects of IL-7 in combination with IL-2 in UCB T-cells.  
The cultured cell products attained using this method have also been used for clinical 
treatment in four patients. The main aim of this study was to assess the safety of the cell 
preparations, and the secondary aim was to identify potential benefits of the treatment. The 
results are presented in scientific paper V. 
III.1 CLINICAL OUTCOME AFTER SINGLE AND DOUBLE UMBILICAL CORD 
BLOOD TRANSPLANTATION (SCIENTIFIC PAPERS I AND II) 
The studies presented in scientific papers I and II were both performed as retrospective 
single-center analyses of the clinical outcome of UCBT. The study in scientific paper I 
included 50 patients that had received a UCBT at CAST, from 2001 to 2010. Patients 
undergoing re-transplantations with a second single or double cord blood graft were not 
included in the study. The patient characteristics were heterogeneous as all UCBT 
recipients were included. There were 30 children and 20 adults. Eighteen of the patients, all 
children, had non-malignant diseases, while the remaining 32 had different hematological 
malignancies. They received conditioning treatment with six different combinations of 
chemotherapy and radiotherapy, the majority of which were full myeloablative regimens. 
All patients received ATG. The donor-recipient HLA-matching varied: a full match of six 
out of the six assessed HLA antigens was achieved in only five patients. The remaining 
grafts were matched on 3 to 5 out of six HLA antigens. The heterogeneity of the patient 
group complicated the interpretation of the results. Additionally, the status of UCB as a 
third choice graft source is likely to have influenced the results of the study. This means 
that other options had been exhausted before a search for a suitable UCB graft was 
initiated, resulting in delayed transplantation even though UCB grafts are more rapidly 
available. Thus, the time from diagnosis to transplantation was longer than what is usual for 
patients at CAST (median 11 months (range 2-148) compared to 9,5 months (range 1-318), 
personal communication Prof Mats Remberger). The third choice status of UCBT also 
resulted in a comparatively high percentage of patients with advanced malignant disease 
(63%) (4). As a consequence, this patient group had an inherently poor prognosis. 
The overall survival of the whole group was 43% at 5 years. Multivariate analysis of factors 
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that could influence survival revealed that increasing age (as a continuous variable, hazard 
ratio (HR) 1.04; P=0.001), acute GVHD grades III and IV (HR 3.43, P<0.001), and 
treatment with MSCs (HR 2.66, p<0.027) were significantly associated with decreased 5-
year survival. Factors that were significantly associated with a lower 5-year survival in the 
preliminary univariate analysis, but were no longer significant in the multivariate analysis, 
were malignant disease (p = 0.03) and DCBT (P = 0.05). As the majority of both the 
recipients of DCBT and the patients with malignant disease were adults, these associations 
could have been partly attributable to age.  
As expected, adult patients with malignant disease had the lowest 5-year overall survival 
(OS, 24%). Conversely, the group with the highest 5-year OS was patients with non-
malignant disease, all children (72%). The low 5-year overall survival in adults with 
malignant disease was partly due to a high relapse rate and partly to a high rate of 
transplant-related mortality (TRM).  
The strong negative correlation between age and survival might be partly attributable to the 
fact that 18 out of 30 of the children had non-malignant diseases, associated with better 
prognosis than malignancies. Children and younger adults are known to have a better 
immune reconstitution after HSCT, better thymus function, and a superior capacity to 
recover from strenuous treatments such as HSCT (219). A recent study in mice has 
suggested that age-related involution of the thymus can be reversed by forced expression in 
thymic epithelial cells of the transcription factor Forkhead box protein N1 (FoxN1) (220). 
This is of course experimental data, but if the concept can be taken into a clinical setting, 
this strategy for improving thymic function would be of considerable interest. 
As is often seen in UCBT, the children in this study received higher doses of total nucleated 
cells (TNC) and CD34+ cells/kg patient weight than the adult patients. They also received 
comparatively better-matched grafts. A high cell dose and a well-matched graft are known 
to positively influence outcome (9, 221, 222).  
None of the five patients with malignant disease that had received a reduced-intensity 
conditioning were alive at the close of the study, while the 5-year overall survival was 33% 
in patients with malignant disease that had undergone a myeloablative conditioning (p = 
0.05). The patients in the RIC-group were all older than 50 years, and thus part of this 
association could be attributable to the negative correlation between age and survival. Due 
to the low number of patients in the RIC-group (only 5, compared to 27 patients in the 
MAC-group) this should be interpreted with caution.  
The negative impact of higher age, acute GVHD grades III-IV and malignant disease on 
survival have been previously described in both UCBT and in HSCT in general (4, 223, 
224). However, the association with MSC treatment has not been described previously. 
Treatment with MSCs was given to nine patients, either infused with the UCB graft as 
engraftment support (n = 7) or given as treatment for GVHD or hemorrhagic cystitis (n = 
2). Of these nine patients, only one remains alive. This patient developed a life-threatening 
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EBV-associated PTLD three months after UCBT that was unresponsive to conventional 
treatment. The patient’s life was saved by successful treatment with an experimental 
therapy devised in the research group: EBV-specific cytotoxic T-cells from a haploidentical 
related donor (197). The 5-year survival of the patients that had received co-infusion of 
MSCs for engraftment support was assessed separately in multivariate analysis to reduce 
the heterogeneity of the groups. Even when the patients that had received MSCs as 
treatment for severe conditions were excluded, there was a significant negative association 
with 5-year overall survival (p = 0.04).  
Our research group has performed additional mechanistic studies of MSC treatment after 
UCBT, and found that treatment with MSCs was significantly associated with reduced T-
cell receptor excision circles (TREC) levels, indicating a poor thymic output (225). The 
reduced TREC levels can have several explanations. Reports have indicated that MSCs 
influence thymus function via effects on the thymic epithelial cells (226, 227). Bone 
marrow MSCs from a mismatched allogeneic donor could be speculated to have a negative 
effect on thymic positive selection of naive T-cells from the graft (225). A percentage of 
intravenously infused cells is known to be trapped in the lungs. This has been shown for 
both MSCs and stem cell grafts (98, 228). Interactions between the MSCs and graft 
lymphocytes in the lungs could be another explanatory mechanism. MSCs are known to 
have immunosuppressive properties and have been shown to have a positive effect in the 
treatment of steroid-refractory GVHD (229, 230). The immunosuppression mediated by 
MSCs seems to be potent and may increase the risk of infectious complications and 
possibly also relapse in certain groups of HSCT recipients. A recent study of risk factors for 
pneumonia-related death in HSCT recipients at CAST have reported a significant 
association between MSC treatment and an increased risk of death by pneumonia (231). 
The etiology was invasive mold infection in a substantial portion of the cases. Increased 
adenovirus-associated mortality after MSC treatment has also been reported in the literature 
(232). In vitro studies have shown that MSCs inhibit stimulation-induced proliferation and 
IFN-γ production of virus-specific T-cells in vitro, which might correlate with increased 
risk of virus infections in vivo (232).  
Jointly these findings have resulted in a discontinuation of the use of MSCs as engraftment 
support in UCBT at CAST. Also, an increased caution is exercised before MSC treatment is 
used in patients with a high risk of severe infection, especially invasive fungal infections. 
Anti-mold prophylaxis should be given to all patients receiving MSC after HSCT. 
These results regarding negative effects of MSC treatment do not, however, stand 
unchallenged. Three previously published studies of MSCs as engraftment support in 
UCBT have not found negative associations between MSC treatment and patient survival 
(233-235). A fourth study even found that co-infusion of MSCs could improve engraftment 
(236). The studies were small, including seven, nine and 13 patients, respectively. Result 
comparisons were performed between the included patients of the four studies and either 
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historical controls (n = 2), or a cohort of contemporary controls, approximately numbering 
3:1 to the number of patients (n = 2). The median follow-up time varied from 8 months to 
6.8 years. No increased infection-related mortality was reported in any of the studies, and 
only one study reported infection-related deaths, at an expected level (233). The 
heterogeneity of the studies and the limited material could possibly have disguised a 
negative association between MSC infusion and overall survival or increased infection-
related mortality. One important parameter that differed between the studies was the use 
and dosage of ATG. The patients included in one study did not receive any ATG, and in the 
remaining three studies equine ATG was used, while rabbit ATG was used in the studies 
included in this thesis. If the different use of ATG had any impact on the outcomes is 
difficult to know. ATG exerts a significant immunosuppression by depletion of T-cells (8), 
potentially to an increased degree in UCBT, and might increase the impact of MSC-
mediated immunosuppression. TREC levels have, as far as it has been possible to ascertain, 
not been analyzed in the patients included in the four studies mentioned above, or in any 
other similar study, preventing a comparison of thymic output after MSCs between the 
studies. The main focus of the trials evaluating MSCs as graft support in UCBT was safety, 
with additional interest in incidence of GVHD, and speed and probability of engraftment. 
Even though survival and rates of infection were studied as well, this might have increased 
the risk of obscuring a possible correlation. 
The incidence of relapse in patients with hematologic malignancies was 29% at 1 year and 
40% at 5 years, which is higher than in HSCT in general at our center (4), but not 
unexpected in a group of patients with advanced malignancies, such as the group studied 
here (6, 124, 237, 238). Transplant-related mortality was 16% at 100 days and 30% at 1 
year, which is similar to what has been reported in the literature (105, 106, 221, 239), but 
comparatively high when compared to results from HSCT with other stem cell sources in 
our center (4).  Possible contributing factors to the high transplant-related mortality include 
the high percentage of patients with advanced malignancies, long diagnosis-to-
transplantation times, and the use of high-dose ATG (8). 
The incidence of acute GVHD grades II to IV was 36% at 180 days, of which 16% was 
grades III and IV. These figures are consistent with previously published data (105, 106, 
239). In multivariate analysis, factors associated with an increased incidence of acute 
GVHD grades II to IV were major ABO blood group antigen mismatch (HR, 2.61; p = 
0.05), and MAC (HR, 4.17; P = 0.047).  
The definition of major ABO mismatch was adapted from Blin et al (240) where ABO 
mismatch in HSCT was defined and categorized as minor, major, or bidirectional. Minor 
ABO incompatibility (e. g. from a type O donor to a type A, -B, or -AB recipient) is 
characterized by the ability of donor B-cells to produce anti-recipient isoagglutinins. Major 
ABO-incompatible HSCT (e. g. from a type A, -AB, or -B donor to a type O recipient) is 
characterized by the presence of preformed anti-donor isoagglutinins. In bidirectional ABO 
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incompatibility (e. g. type A donor to a type B recipient), a combination of both major and 
minor mismatches is present.  
The finding of increased incidence of GVHD in patients transplanted with ABO-
mismatched grafts is partly supported by previous studies, but mainly in recipients of a 
minor ABO-mismatched graft after transplantation with stem cells from adult graft sources 
(241). There is also, however, contradicting results in the literature: several studies 
exploring risk factors of GVHD have not found any such correlation (241, 242). 
Specifically, a study was performed in 503 UCBT recipients to assess if ABO mismatch 
increased the risk of GVHD in the UCB setting. No such correlation was found, and the 
authors speculated that the naivety of UCB T-cells might be protective against triggering of 
GVHD against ABO-related antigens (243). There is no obvious explanation for the 
discrepancy between the results published there and the results in scientific paper I, but 
differences in graft handling, use of ATG, or other transplant practices might have 
influenced the results. In the reporting center of the study discussed above, ATG is used 
only in a third of the patients, namely those that have received less than two cycles of 
chemotherapy during the three months prior to transplantation (239), which might have 
been of importance to the outcome.   
The study presented in paper I also explored chimerism development in this patient group 
and these results are discussed under the Chapter III.2. 
In summary, the findings of scientific paper I showed that treatment with MSCs was 
associated with a lower 5-year survival after UCBT. This finding caused MSC infusion to 
be discontinued as engraftment support in this context. The low survival rate of adult 
patients with malignant disease in this study is an incentive to explore other alternative 
graft sources in these patients. The poor outcome in adult patients with malignant disease 
that received a RIC was justifies increased consideration in the choice of conditioning 
regimen for this patient group, though the patient number was low and the results should be 
interpreted with caution.  
The scope of the study presented in scientific paper II was limited to patients that had been 
transplanted with DCBT. DCBT recipients treated at CAST between 2004 and 2008 were 
included, in total 12 patients. The main aim of the study was to explore chimerism 
development after DCBT, leading to exclusion of five patients due to early re-
transplantation (n = 2), early death (n = 2) and inability to separate the two cord blood units 
with chimerism analysis (n = 1). Of the seven remaining patients, five had received a MAC 
and two had received a RIC. All patients were treated with ATG, at a total dose of 8 mg/kg. 
Three patients out of seven developed acute GVHD, in two of the cases classified as grades 
III–IV. Four patients of seven died during the study, due to GVHD (n = 1), relapse (n = 2) 
and PTLD (n = 1). The rate of infectious complications was relatively high, with five cases 
of CMV infection, one case of varicella-zoster infection and one case of EBV-associated 
PTLD. Possibly, this could be a consequence of the high dose of ATG administered to 
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recipients of DCBT. Consequently,the ATG dose used in this setting have been reduced at 
our clinic. 
The study of chimerism development of the patients in scientific paper II is described in 
Chapter III.2.  
III.2 CHIMERISM DEVELOPMENT AFTER UMBILICAL CORD BLOOD 
TRANSPLANTATION (SCIENTIFIC PAPERS I, II AND III) 
Chimerism development was a major focus of the studies described in scientific papers I 
and II. We aimed to thoroughly describe the dynamics of chimerism development in UCBT 
recipients, and to attempt to elucidate the underlying mechanisms. The frequent and 
comprehensive chimerism analyses performed routinely at CAST for all HSCT recipients 
provided a solid platform from which to launch such studies.  
In the study presented 
in scientific paper I, 
we compiled the 
chimerism data for 
the CD3+, CD19+, 
and CD33+ cell 
lineages at set time 
points: 3, 6, 12 and 24 
months after UCBT. 
We found that 
complete donor 
chimerism in all three 
cell lineages was 
reached in 22 patients out of 40 assessable at 3 months (55%). It should be noted that the 
proportion of patients with DC at a given time point, especially at the earlier time points, 
was limited by a lack of data, in one or more of the cell lineages, in a number of patients 
due to technical difficulties or low cell counts. The number of patients with DC in a given 
lineage varied over time, as is illustrated in Fig 9.  
Median time to DC differed between the three cell subsets:  35 days for the CD19+ cell 
lineage, 28 days for the CD3+ cell linage, and 21 days for the CD33+ cell lineage. This 
could be a reflection of the dynamics of post-UCBT immune reconstitution (162). 
In multivariate analysis, TBI-based conditioning was associated with DC for all cell 
lineages: in the CD19+ cell lineage, HR 2.93 (p = 0.002); in the CD3+ cell lineage, HR 
3.16 (p = 0.003); and in the CD33+ cell lineage, HR 3.49 (p = 0.001). All patients who 
received TBI-based conditioning achieved DC in all cell lineages, while only 69-72% of the 
patients treated with chemotherapy-based conditioning reached DC in the different cell 
lineages (P=0.02-0.04). Additionally, the median time to DC was also significantly shorter 
Figure 9. Chimerism development in UCBT recipients at CAST. The graph shows the 
percentage of patients with donor chimerism in the patient group. The cell lineages are 
plotted separately. 
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in patients that had received TBI-based conditioning than in patients pre-treated with only 
chemotherapy in the CD19+ cell lineage: 28 days vs. 56 days (P=0.04), and in the CD33+ 
cell lineage: 21 days vs. 28 days (P=0.03).  
TBI-based conditioning treatment is mainly given to patients with ALL or lymphoma, who 
are usually heavily treated with chemotherapy prior to HSCT. This may partly explain the 
high probability and rapid development of DC in this patient group. Chemotherapy can 
cause chronic bone marrow damage resulting in chronic disruption of hematopoietic 
function (244). This can impair the host’s capacity to react against the transplanted immune 
system, as indicated by a decreased risk of rejection in heavily pretreated patients (245). 
The association between conditioning containing TBI and an increased probability of DC 
that have been described here is supported by the results of a subsequent study at CAST 
investigating long-term mixed chimerism after HSCT with stem cells from adult graft 
sources in patients with non-malignant disease (246). Patients with long-term mixed 
chimerism were less likely to have received TBI prior to HSCT than the DC controls. 
However, in a recent study of chimerism development in children after UCBT, no 
significant association was seen between conditioning containing TBI and development of 
DC (247). One possible partial explanation to these contradictory results is that all the 
patients in the latter study were children, who are known to have a superior capacity of 
recovery after chemotherapy (248, 249). Another study comparing myeloablative 
conditionings with cyclophosphamide and busulphan or cyclophosphamide and TBI to RIC 
with fludarabine and low dose TBI did not find any significant difference in either the 
proportion or kinetics of DC development for the three conditioning regimens (250). Our 
analysis compared all TBI-containing conditionings regardless of classification as RIC or 
MAC to all conditionings containing only chemotherapy, hence these data are difficult to 
interpret in relation to the ones presented in scientific paper I. Two other differences 
between the studies might have influenced the disparate findings. The patients included in 
the TBI group of scientific paper I almost exclusively suffered from either ALL or 
lymphoma, while only approximately 30% of the two TBI groups in the other studies were 
diagnosed with these diseases. This study also analyzed T-cell chimerism and total 
leukocyte chimerism, while our analysis included T-cell, B-cell and myeloid cell 
chimerism, which might also have influenced the findings. 
There were factors associated with a significantly increased rate of DC development in 
univariate statistical analysis that was not significant in the subsequent multivariate 
analysis: malignant disease for DC in the CD19+ (P=0.012) and CD33+ (P=0.001) cell 
lineages, acute GVHD grades II to IV for DC in the CD3+ cell lineage (P=0.01), and higher 
CD34+ cell dose for DC in the CD19+ cell lineage (P=0.01). Higher cell dose has been 
found to associate with development of DC previously (250). 
The association between acute GVHD and an increased proportion of DC in the CD3+ cell 
lineage is consistent with previously published data in UCBT and in HSCT with adult stem 
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cell sources (247, 251). This might be partly due to the role of alloreactive T-cells in 
establishing and maintaining engraftment after HSCT. Strong donor T-cell alloreactivity is 
thought to mediate immune-mediated destruction of recipient cells (250). However, 
strongly alloreactive donor T-cells also cause an increased risk for acute GVHD. 
Conversely, strong alloreactivity in recipient T-cells can cause graft rejection if not 
sufficiently controlled by the conditioning and immunosuppressive treatment (251). Mixed 
chimerism in the CD3+ cell lineage is considered more likely if the alloreactivity of donor 
T-cells is weak, since it can be thought to permit persistence of recipient T-cells and 
development of tolerance (251, 252). An association between mixed T-cell chimerism and 
relapse has been debated, with some reports supporting this correlation, while others have 
failed to find such an association (247, 250, 251, 253).  
The results of scientific paper I showed that a higher rate of transplant-related mortality was 
associated with DC in the CD3+ cell linage (P=0.024). This might be a secondary to the 
association with GVHD, which is negatively associated with survival, as discussed in 
Chapter III.1. Jointly, available knowledge indicates a central role for T-cell chimerism in 
the transplant outcome. 
The association between malignant disease and DC is also consistent with previously 
published data after HSCT with UCB, bone marrow transplantation and peripheral blood 
stem cell transplantation (PBSCT) (158, 247). Patients with malignant disease have 
undergone more extensive pre-treatment, essentially reducing the risk of rejection and 
decreasing the likelihood of MC development (245). 
A proportion of patients retained stable MC over time. MC is thought to reflect 
immunologic tolerance between donor and recipient (156, 251, 254-256). (It is, however, 
important to separate stable mixed chimerism, which is discussed here, from an increasing 
recipient chimerism heralding rejection or relapse in malignancy.) Several factors can be 
speculated to have contributed towards development of tolerance in this study: the low cell 
dose leading to slow engraftment, creating the opportunity for tolerance development 
and/or the fact that all the patients received ATG (8, 105, 222). Tolerance in this setting is 
an interesting immunological phenomenon as it necessarily is a consequence of two 
genetically different immune systems existing side by side. This co-existence could be 
speculated to result in an increased immune diversity, leading to a resulting joint immune 
system recognizing a wider spectrum of antigens. Tolerance can also be speculated to be 
accompanied by an impaired general immune reactivity, as it reflects low donor-recipient 
reactivity (156, 257). As discussed above, there is an ongoing debate regarding if mixed T-
cell chimerism is a risk factor for relapse in malignant disease. Stable mixed chimerism has 
been found to associate with low rates of GVHD (158, 246, 247, 250, 251, 253), consistent 
with a state of tolerance. This could theoretically lead to increased relapse risk since GVHD 
and GVL are known to be associated (5, 258, 259). Mixed chimerism has not been 
described in the literature to cause an increased risk for infectious complications, as far as 
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has been possible to ascertain. One study has reported increased MC development and an 
increased risk of infections after alemtuzumab compared to after ATG, but the treatment 
itself rather than the mixed chimerism state was considered to cause the increased 
susceptibility to infections (260). A study performed at CAST with the aim of exploring the 
clinical outcomes of patients with long-term MC found that the risk of blood stream 
infection seemed to be lower in those patients compared to controls with donor chimerism 
(246).  
Mixed donor-donor chimerism, where persistence of both donors transplanted in DCBT is 
seen in the absence of remaining recipient cells, was the main focus of scientific paper II. 
MDC can be considered a subtype of complete DC, as no recipient cells remain, but can 
also be defined as a kind of MC, as the immune system is composed of cells from two 
genetically different host origins. This is a relatively new phenomenon, as double UCB 
graft transplantation is more recent HSCT method. The number of reported cases is small as 
the majority of previously published studies have reported that sustained hematopoiesis 
after DCBT is almost exclusively derived from only one of the donated units (261-264).  
The results presented in scientific paper II showed that four of the seven patients had 
complete DC in all cell lineages in chimerism analysis one month after DCBT. Out of those 
four, two had a MDC in all three cell subsets. One patient showed high levels of recipient 
cells in both T-cells and myeloid cells in peripheral blood, indicating a threatening 
rejection. However, in the bone marrow, 90% of CD34+ cells were of donor origin. He 
received cultured umbilical cord blood T-cells, and his further clinical history is described 
in Scientific Paper V and in chapter III.3.  
At four months after UCBT, three out of five assessable patients had complete DC in all 
cell lineages, and one of them still retained a mix of both donors present in all cell lineages. 
One of the patients with MDC one month after UCBT died of a severe acute GVHD at 3 
months, still retaining this chimerism status. A fourth patient presented with 20% percent 
recipient cells in the B-cell compartment. The remaining 80%, and 100% of both the CD3+ 
and CD33+ cells, were of mixed donor origin, with a proportion of each donor in all cell 
lineages. A full MDC developed in this patient at six months.  
The two patients that developed MDC at four and six months after DCBT, respectively, 
retained this chimerism pattern until the end of this study, at 25 and 35 months after 
transplantation, respectively. Both patients were then in good clinical condition.  
Finding two patients with long-term MDC was unexpected, and of particular interest due to 
the scarcity of previously reported cases. At the time when papers II and III were written, 
only three patients with MDC had been described. Five additional patients have since then 
been reported (263, 265-272). The follow-up times for the eight reported patients were 12 
months (2 patients), 16 months (2 patients), 24 months (3 patients), and 28 months (1 
patient), respectively. As both patients were doing clinically well and had long-term stable 
MDC at 25 and 35 months, this finding provided a unique opportunity to study this 
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chimerism pattern further.  
Existing knowledge remains insufficient to predict which patients will develop persistent 
mixed donor chimerism after DCBT. The two patients studied here did not differ from the 
other patients regarding the given cell dose, percentage of viable cells or HLA-matching.  
Neither of the two patients developed GVHD. This indicates that the state of tolerance in 
recipient-donor MC was likely to exist also in MDC. It is difficult to determine if the 
absence of GVHD is a consequence of the tolerance in MDC, or if the long-termed mixed 
chimerism is allowed to persist due to the absence of GVHD. It has been reported that 
patients with MC have reverted to complete DC after development of GVHD (251, 273). 
The GVHD then signals the breaking of the tolerant state.  
The development of long-term MDC in our material might have been facilitated by the use 
of high dose ATG, 8 mg/kg. This high dosage was selected with regard to the HLA 
disparity found in the majority of UCBTs. A high dose of ATG is associated with a delayed 
development of donor chimerism after HSCT (8, 274). In the present study, the high ATG 
dose in combination with the low T-cell dose in the graft and the naivety of the UCB T-
cells could have caused high levels of ATG to remain after the transplantation, causing an 
unwanted degree of in vivo T-cell depletion. This in vivo T-cell depletion could have 
permitted tolerance and consequent MDC development. In support of this supposition, T-
cell depletion in major HLA-mismatched bone marrow infusion have been described to 
cause tolerance and mixed chimerism in animal models (275). This is one explanatory 
model for the findings of scientific paper II. However, further studies were considered 
necessary to explore the causes and immunological consequences of this phenomenon.  
We continued the investigations into the properties of MDC in scientific paper III. The two 
patients with MDC were there compared to control patients with single-unit DC after 
DCBT or UCBT. The patients were male, 20 and 30 years old. The underlying diseases that 
had led to transplantation were AML and B-cell lymphoma. They both received MAC. As 
stated above, neither developed GVHD.  
The phenotypical and functional characteristics of the immune systems of the MDC 
patients were studied by flow cytometry. This revealed that the frequencies of T-, B-, NK-
cells and monocytes did not differ markedly between MDC patients and single unit DC 
controls. There were also no differences in ‘dim’ and ‘bright’ NK-cell subset frequencies, 
or in memory B cells. However, the frequencies of the TCR-γδ T-cells and FoxP3+CD25+ 
possible regulatory T-cells (there are difficulties in separating activated effector T-cells and 
regulatory T-cell based on these two markers (33)) were lower in the MDC patients 
compared to the control group. 
Expression of the cell surface markers CD45RO and CCR7 was used in this thesis to 
characterize different subsets of T-cells, as discussed in chapter I.1.iii (11, 43, 44). 
CD45RO- CCR7+ were termed naive T-cells, CD45RO+ CCR7+ were central memory T-
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cells, CD45RO+ CCR7- were effector memory T-cells, and CD45RO- CCR7- were 
considered terminally differentiated memory T-cells. The T-cell maturation profile of the 
MDC patients was discovered to be more naive than that of the single unit DC controls: the 
frequencies of naïve cells were noticeably higher, and the frequencies of effector memory 
T-cells lower.  
To further investigate the immunological properties of MDC, a comparison of the cord 
blood units within each of the patients was also performed, to identify potential individual 
phenotypes. Retrospective chimerism data revealed a fluctuation of the two units over time 
(Fig. 10). This could be due to immunological processes or to random variations in cell 
trafficking in the peripheral blood. To examine the two units separately within each patient 
we performed a flow cytometric typing assay with anti-HLA-A3 in one of the patients, and 
a PCR-based chimerism analysis for the other patient, to enable further analysis. This 
revealed that both patients had a major and a minor unit, as regards the proportion of 
circulating cells. The minor unit in both patients displayed a higher prevalence of NK cells.  
 
Figure 10. Chimerism development in the two patients with MDC. The figures shows the chimerism results for the 
recipient and the two donors in the CD3+, CD19+ and CD33+ cell linages. The panels on the left pictures the 
chimerism results of the patient with AML, while the panels to the right present the results for the patient with 
lymphoma. 
The patient with AML was not included in further analyses due to disease relapse (seen as 
an increase of CD33+ cells of recipient origin in Fig. 10, panels on the left side). Hence, the 
following flow cytometry typing assays were performed in a single patient. In this 
remaining patient, the minor unit had lower frequencies of memory B-cells and TCR-γδ T-
cells, but higher frequency of possible regulatory FoxP3+CD25+ T-cells. 
To study the TCR repertoire of the two cord blood units, a flow cytometry typing assay for 
15 different Vβ subsets was performed. This indicated polyclonal patterns of TCR β-chain 
usage, and was comparable between the two units. 
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Differences in the T-cell maturation profile of the two cord blood units was investigated by 
flow cytometry of the expression of CCR7 and CD45RO. The minor unit displayed lower 
frequencies of both central memory and effector memory T-cells, and higher frequencies of 
naïve T-cells compared to the major unit. 
We further analyzed T-cell and NK-cell function, using stimulation assays, in the remaining 
patient to further investigate immune cell function in MDC. Result comparison was 
performed between the MDC patient and the control patients with single unit DC, and 
between the two UCB units in the MDC patient. Peripheral blood mononuclear cells 
(PBMCs) were stimulated with ionomycin and PMA, and analysis of cytokine production 
was performed by flow cytometry. The frequency of T-cells producing IFN-γ, TNF-α and 
IL-2 was lower in the MDC patient, while the proportion of T-cells producing IL-17 was 
comparable to the single unit controls. When the two cord blood units were compared to 
each other, we found that the T-cells of the major unit tended to produce more IFN-γ, TNF-
α and IL-17. In contrast, the minor unit had slightly higher frequencies of IL-2-producing 
cells. 
NK-cell function was assessed by stimulation of PBMCs with PMA or K562 cells, 
followed by flow cytometric analysis. The frequencies of NK-cells responding to PMA 
with CD107a up-regulation, a measure of degranulation, and IFN-γ production, were 
comparable between the MDC patient and the single unit controls. However, when 
stimulated with K562 cells lacking MHC class I molecules, a higher percentage of NK-cells 
in the patient with MDC up-regulated CD107a compared to NK-cells of control patients 
with single unit chimerism. The NK-cells of the separate units in the MDC patients both 
responded with up-regulation of CD107a and IFN-γ production in response to stimulation 
with mitogen and K562 cells, but the majority of the NK-cells that up-regulated CD107a 
were found in the major unit. This finding suggests that even though there is a state of 
tolerance in the MDC system, the potential of an NK-cell response per se is not impaired. 
We could not detect any obvious functional advantages or disadvantages of MDC in the 
two patients included in the study, compared to the single UCB unit DC controls. We found 
that the MDC patients had fewer effector memory T-cells and TCR-γδ T-cells, and a more 
naive T-cell phenotype compared to the control patients. NK-cell function was seen to be 
comparable between the MDC patient available for further analyses and controls, with a 
suggestion of increased NK-cell reactivity against MHC-deficient targets in the MDC 
patient. NK-cells are regulated partly by inhibitory and activating killer cell 
immunoglobulin-like receptors (KIRs) that recognize certain HLA-C molecules (276). 
When NK-cells are confronted with allogeneic target cells that do not express inhibiting 
ligands, NK-cell alloreactivity may occur. The donor units of the two patients with MDC 
were HLA-C matched, which might induce mutual NK-cell tolerance. Some support for 
this hypothesis was found when studying HLA-C matching in the DCBT recipients with a 
single prevailing unit in scientific paper II. The units used in those patients were not 
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matched for HLA-C, with the exception of one patient. A plausible reason to why this 
patient did not develop MDC, despite receiving HLA-C matched cord blood units, could be 
the extremely high inter-unit difference in CD34+ numbers (22 to 1) and TNC (3 to 1) in 
favor of the prevailing unit. 
The importance and consequences of HLA-C matching in HSCT has been discussed in 
other contexts. HLA-C/KIR mismatch between donor and recipient has been shown to 
positively influence the GVT effect in haploidentical HSCT (277), although there are some 
contradictory reports in unrelated HLA-mismatched HSCT (278, 279). In UCBT, HLA-
C/KIR mismatch has been associated with less relapse as well as better survival (280). 
Moreover, a lower relapse risk has also been reported for DCBT compared to single UCBT, 
regardless of HLA-C (281). 
The dynamics of chimerism development after DCBT, with special focus on single unit 
dominance, have attracted widespread interest. Potential predictive factors for unit 
dominance have been studied and debated over several years and results have been 
contradictory. Parameters suggested to be predictive have included: HLA-matching, total 
nucleated cell dose, CD34+ or CD3+ cell doses, viability, ABO typing, gender match and 
order of unit infusion. All these have been found to correlate with unit dominance in one or 
several studies, but none have been uniformly shown to predict which unit will prevail 
(239, 263), and, thus, no consensus has been reached. The CD3+ T-cell dose in the graft, 
and the amount of CD8+ T-cells, in one study especially naïve CD8+ T-cells, have been 
found to predict which unit eventually prevails after DCBT (261-263, 271). The increased 
risk of GVHD and reduced risk of relapse described in DCBT compared to single UCBT 
might indicate that immune reactions between the units and between the donors and the 
recipient, are more pronounced after DCBT and might play a role in single unit dominance 
(263).  In vitro data supporting a graft-versus-graft immune interaction for unit dominance 
has been published previously. In this study, in vitro assays showed that the cord blood 
mononuclear cells from the dominant unit were able to develop a more pronounced 
cytotoxic activity than the mononuclear cells of the minor unit in a mixed lymphocyte 
reaction setup (264). Another mechanism for unit dominance that has been suggested is 
CD8+ T-cell mediated rejection of the losing graft by the prevailing unit (262, 271). This is 
supported by in vitro findings showing that CD8+ memory T-cells of the dominant unit 
produces IFN-γ if challenged by cells from the non-engrafting unit, but not when 
challenged with third party cells (262). No allogeneic response was detected in the CD8+ 
memory cells of the non-engrafting unit against cells from the dominant unit. In patients 
with mixed chimerism, no alloreactivity-induced IFN-γ production was triggered in the 
CD8+ memory T-cells of any of the units (262).  Other groups have suggested that the 
potential NK-cell alloreactivity of one unit might contribute to unit dominance (277, 280). 
However, there is at present still no consensus regarding factors with predictive value for 
unit dominance.  
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It is difficult to identify factors that influence development of MDC due to the scarcity of 
cases. We proposed in scientific papers II and III that high-dose ATG and HLA-C match 
might facilitate development of MDC. The in vivo T-cell depletion caused by high-dose 
ATG, and possible NK-cell tolerance between units due to HLA-C match could increase 
the chances of inter-unit tolerance. T-cells reconstitute more slowly after DCBT compared 
to HSCT with adult hematopoietic cell sources, and the T-cell numbers in UCB is also 
significantly lower. High-dose ATG may have too large an impact in the DCBT setting (8, 
162, 263). A recent meta-analysis of chimerism development after DCBT collected the 
published cases of MDC and summarized the present state of knowledge (263). Excluding 
the possible causes of MDC discussed in this thesis, few other factors have been suggested 
to influence development of this chimerism pattern. One factor proposed to be important in 
MDC development is the type of immunosuppression used, and the timing of its 
discontinuation. Immunosuppressive treatment can have bearing on whether a tolerizing 
milieu will arise in the host to facilitate MDC development.  
The findings presented in scientific papers II and III did not show that this MDC confers 
any obvious advantages in immunity. The immune system in the patients with MDC 
seemed to have a more naïve immune profile than single UCB unit chimerism controls, 
which could be an implication of impaired immunological memory formation. However, 
MDC did not seem to entail any obvious clinical disadvantages, as two of the three long-
term survivors in scientific paper II showed this chimerism pattern. One of the patients with 
MDC is still doing well today, many years after transplantation, and is the only one still 
alive of the 12 DCBT recipients included. Of note, the patient material is small and the 
results must thus be interpreted with caution.     
III.3 CULTURE OF UMBILICAL CORD BLOOD T-CELLS FOR USE AS DONOR 
LYMPHOCYTE INFUSIONS (SCIENTIFIC PAPERS IV AND V) 
The second aim of this doctoral project was to develop adoptive cell therapies in the UCBT 
setting. Donor lymphocyte infusion is the most common form of ACT after HSCT, and is 
an important treatment for relapse of hematological malignancy. The lack of conventional 
DLI is a considerable drawback of UCBT, and several methods to develop alternatives in 
vitro have been evaluated (10, 11, 198-200). We attempted to address this issue in the 
studies presented in scientific papers IV and V. We chose to culture bulk T-cells from an 
aliquot of the original graft (10, 11, 198, 200) to imitate conventional DLI as closely as 
possible. Other approaches that have been attempted previously are discussed in chapter 
I.3.iii. 
The culture protocols used in T-cell based ACTs usually rely on expansion induced by 
artificial TCR/co-receptor stimulation combined with cytokines (10, 198, 200). A clinical 
trial using activated and expanded conventional DLI, prepared with a very similar method 
as used here, has shown promising results regarding anti-tumor efficacy with only a 
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moderate risk of GVHD (282). This is in accordance with reports showing that cultured T-
cells are less alloreactive than un-manipulated T-cells (283, 284). A low risk of inducing 
GVHD would be beneficial in a UCB DLI product, but the decreased alloreactivity might 
also implicate a decreased GVT effect.  
The choice of cytokines is of major importance in the production of a purpose-fitted cell 
product. The study of UCB T-cell culture for putative ACT was initiated in the research 
group previous to the work described in this thesis, using a protocol relying on anti-CD3/-
CD28-covered paramagnetic beads and high-dose IL-2 (11). IL-2 was the only cytokine 
available in clinical-grade preparations for T-cell expansion at the start of this project, and 
is comprehensively studied in this setting (11, 285). The initial feasibility study published 
by our group on UCB T-cell culture showed that the use a 5% aliquot obtained at 
transplantation from a clinical UCB graft yielded sufficient numbers of T-cells for the 
cryopreservation of DLI and could be performed in accordance to good manufacturing 
practice (GMP) regulations. The cultured T-cells had an activated phenotype, with a 
majority of the cells having characteristics of central memory and effector memory T-cells. 
There was a polyclonal usage of β-chains in the cultured cell population, indicating a 
diverse TCR repertoire. In functional assays, the cultured UCB T-cells responded normally 
to non-specific T-cell stimuli and to allogeneic cells (11).   
Additional cytokines have become available in clinical grade preparations, making he 
choice of cytokines for in vitro T-cell culture increasingly complex. A culture protocol 
relying on artificial TCR stimulation and high levels of IL-2 has inherent drawbacks, like 
significant up-regulation of apoptosis markers (10). Also, T-cells are prone to activation-
induced apoptosis after strong TCR stimulation, and this tendency is more pronounced in 
UCB T-cells (286). The massive proliferation during the in vitro culture could also limit the 
proliferative potential of the cell product in vivo (211). However, one of the benefits of 
UCB in this context is the comparatively longer telomeres associated with T-cells of this 
origin compared to adult T-cells (287), which might indicate an increased mitotic capacity.  
Another issue that needs to be addressed is the risk of cytokine deprivation in vivo, 
resulting in anergy or apoptosis, due to the much lower cytokine levels in vivo compared to 
in vitro (10, 198, 211).  
The addition of IL-7 was explored in scientific paper IV as a step toward a more functional, 
long-lived UCB DLI product. The rationale for this was that 1) IL-7 had become available 
in clinical grade preparations, 2) several of the unique characteristics of IL-7 were 
speculated to decrease the risk for apoptosis and exhaustion in the cultured cells. IL-7 is a 
homeostatic cytokine required for the survival and development of T-cells (67-71). We 
wanted to explore the possibility of using both IL-2 and IL-7 in the cultures, to enable a 
decrease of the IL-2 levels. A lower IL-2 level might lessen the risk of cytokine 
deprivation, while the addition of IL-7 could have anti-apoptotic and proliferative effects. 
Also, IL-2 has been found to increase responsiveness to homeostatic proliferation induced 
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by IL-7 and IL-15 in CD8+ memory T-cells (84). This suggests that the combination of IL-
2 and IL-7 could increase the efficiency of CD8+ T-cell proliferation in cultures. CD4+ 
UCB T-cells have a comparatively higher expression of the IL-7 receptor α-chain (CD127) 
than adult CD4+ T-cells, possibly making them more responsive to IL-7 (83).   
The effects of IL-7 were explored 
in the presence of different levels 
of IL-2. The culture protocol is 
found in Table 2. After the culture 
of four UCB units under the 12 
conditions in Table 2, certain 
trends were clearly visible in the 
proliferation rates of the cultured 
cells. We chose to continue with 
culture of further UCB units in 
only the four culture conditions 
with the most interesting 
preliminary results (C5, C6, C11, 
and C12). The choice was based 
on (a) the comparatively high IL-2 concentrations used in the protocol for UCB T-cell 
culture previously published (15) (C11 and C12), and on the lower level of IL-2 that 
combined with IL-7 resulted in the highest fold expansion (C5 and C6). We compared C5 
with C6, C11 with C12, and C6 with C11. The latter comparison was made to study 
differences between the protocol that we have used in the previous studies (C11) and the 
condition with the best preliminary results (C6). 
We found several phenotypic differences between cells grown with identical levels of IL-2 
but in the presence or absence of IL-7. To begin with, the median fold expansion was 
higher in T-cells cultured with both IL-2 and IL-7, compared with T-cells cultured with IL-
2 alone. This was statistically significant in C6 compared to C5 (P=0.0078), in C12 
compared to C11 (P=0.0098), and in C6 compared to C11 (P=0.0098). Increased 
proliferation induced by IL-7 in UCB T-cell culture has been reported previously (198). 
Here, the effect was striking, and allowed an almost 85% reduction of the level of IL-2 
without impacting on the end-of-culture cell numbers. 
The CD4+/CD8+ T-cell ratio was higher in cultures exposed to IL-7, reflecting a 
comparatively higher percentage of CD4+ T-cells and a lower proportion of CD8+ T-cells, 
than in their counterparts cultured with IL-2 only (Figure 11a). Our previously published 
study showed a low CD4+/CD8+ ratio in UCB T-cells cultured with high-dose IL-2, lower 
than in both peripheral blood and in fresh UCB (15). Similar results have been published 
previously in a study with similar set up (10). Here, IL-7 was seen to skew the ratio towards 
that seen in peripheral blood. This could be partly due to the fact that IL-7 is critical for 
Culture protocol
Cytokine content in media
Condition nr. IL-2 (IU/ml) IL-7 (20 ng/ml)
1  -  -
2  -  +
3 50  -
4 50  +
5 100  -
6 100  +
7 200  -
8 200  +
9 400  -
10 400  +
11 600  -
12 600  +
Table 2. Culture protocol used in scientific paper IV. 
 
 60 
CD4+ memory-cell survival, but less ubiquitous for the sustenance of CD8 + memory T-
cells (70, 81). Also, the relatively high concentration of IL-7 used here could have led to 
preferential expansion of CD4+ T-cells, as CD4+ T-cells have been shown to require higher 
IL-7 concentrations for effective proliferation compared to CD8+ T-cells, an effect 
mediated by Lck (66). 
The developmental and 
functional T-cell phenotype 
has been found to impact of 
the efficacy and longevity of 
the adoptively infused cells, 
as was discussed in chapter 
I.3.I. Central memory T-cells 
have been shown to have 
superior efficacy and 
persistence (203-205), while 
effector memory T-cells have 
been shown to have superior 
potential to acquire and exert 
effector functions in vitro 
(209, 210). Though both 
memory subsets may have 
advantages in adoptive 
therapy, central memory T-
cells might preferable due to 
the importance of in vivo 
persistence of transferred 
cells. New strategies for 
inducing the requisite 
phenotype will be needed, 
and short culture time and 
minimal cytokine exposure 
have been suggested in the 
literature (211).  
With this in view, the need to assess the memory phenotype of cultured cells was evident. 
Thus, the frequency of different memory T-cell phenotypes was analyzed based on the 
expression of CD45RO and CCR7, as described in Chapter III.2. Addition of IL-7 skewed 
the CD4+ T-cell compartment toward higher frequencies of effector memory T-cells at the 
expense of central memory T-cells (Figure 11b). This was statistically significant for C6 vs. 
C5  (P = 0.0137), C12 vs. C11 (P = 0.0039) and C6 vs. C11 (P = 0.0098). There were no 
significant differences for these two memory phenotypes in the CD8+ T-cell population. 
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Figure 11. a) shows the CD4+/CD8+ T-cell ratio of the cultured T-cells. One 
dot represents one culture condition in one culture. 
b) The median percentage of different memory development phenotypes are 
shown for conditions 5, 6, 11 and 12. 
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The CD4+ T-cell findings are in contrast to a previous report of UCB T-cell expansion with 
IL-7 (10 ng/mL) and a single set concentration of IL-2 (100 IU/ mL). There, a majority of 
the T-cells maintained a naive phenotype, there defined as CD45RA+ CD62L+ T-cells, 
after 14 days of culture (48). This might indicate that different levels of IL-7 produce 
different effects in UCB T-cell cultures. Previous studies have shown that low doses of IL-
7 induce T-cell development, while high doses can block development at an early stage. 
Also, low concentrations of IL-7 were found to provide survival signals, while higher 
concentrations enabled proliferation (66, 69, 77). This indicates dose-dependent effects 
exercised by IL-7 in different concentrations, and suggests that further studies titrating the 
optimal IL-7 dose might be useful. Both CD4+ and CD8+ central memory T-cells are able 
to differentiate into effector T-cells in response to homeostatic cytokines such as IL-7 (42, 
82, 84). However, whereas a large proportion of CD4+ T-cells differentiate into a late-stage 
effector phenotype in response to homeostatic cytokine signaling, CD8+ T-cells react more 
heterogeneously, resulting in a mixed cell population of effector T-cells, effector memory 
and central memory T-cells, and even naïve T-cells upon exposure to homeostatic cytokines 
(84). This might partly explain the shift from central memory to effector memory T-cells in 
the CD4+ compartment. Another possible explanation to this shift is that CD4+ memory T-
cells have a higher proliferation rate than naïve CD4+ T-cells in response to IL-7 (78). This 
finding could be of importance for the potential longevity of the cultured cells in vivo, as a 
study with adoptive transfer of CD8+ T-cells in macaques have demonstrated that central 
memory, but not effector memory, CD8 + T-cells persist in vivo after transfer (203). As the 
optimal memory T-cell phenotype for ACT is yet unknown, further studies are necessary to 
determine how to further engineer the UCB T-cell cultures in the future. 
The addition of IL-7 decreased the frequency of CD69+ T-cells compared to cultures 
without IL-7 in C12 versus C11 and in C6 versus C11. CD69 is considered an early 
activation marker in T-cells (288). Lower frequencies of CD69+ cells in the presence of IL-
7 might reflect different activation kinetics in UCB T-cells cultured in the presence of this 
cytokine. See also Figure 3 for an overview of T-cell activation markers. 
There were no significant differences in AnnexinV or 7-Aminoactinomycin D staining, the 
markers for apoptosis and cell death used in this study. This finding was unexpected, as IL-
7 is known to have anti-apoptotic effects by maintaining the length of telomeres and 
inhibiting pro-apoptotic signals (81, 289-292). A previous study with a similar set up using 
anti-CD3/-CD28 beads, IL-2 and IL-7 (10 ng/ml medium, half of the concentration used in 
scientific paper IV) showed that the combination of IL-7 and IL-2 resulted in a higher 
percentage of viable cells compared to IL-2 only (198). The pro-survival effects of IL-7 
have, as discussed above, been found to be of a dose-dependent character (66, 69, 77). 
Another factors that can influence the anti-apoptotic effects of IL-7 is intensive TCR 
stimulation which inhibits the signaling through the IL-7 receptor, lessening the pro-
survival effects of IL-7 in adult blood T-cells (291). Also, prolonged IL-7 signaling has 
been shown to induce proliferation, production of IFN-γ and finally IFN-γ-triggered cell 
 62 
death in adult naive CD8+ T-cells. However, intermittent (not continuous) IL-7 stimulation 
supported the survival and quiescence of CD8+ T-cells (290). Homeostatic TCR 
stimulation was found to protect against apoptosis in this study by interrupting IL-7-
mediated signals, naive CD8+ T-cells with insufficient TCR affinity for self-ligands 
underwent apoptosis in the presence of homeostatic levels of IL-7 (290). It could be 
speculated that the yield of viable UCB T-cells at the end of culture in our system could be 
increased if intermittent and/or lower levels of IL-7 was applied.  
 Many strategies have been explored for engineering ACT products to induce longevity and 
efficacy in vivo. Short culture time and different cytokine combinations to maintain a 
comparatively naïve phenotype have been tried, aiming to preserve proliferative capacity 
and enable the cultured cells to home to secondary lymphoid organs, (211). The recent 
introduction of chimeric antigen receptors (186, 187), which can retarget T-cell specificity, 
is a strategy to decrease the need for extensive proliferation in vitro in ACT settings with a 
single target antigen. Other approaches include strategies to improve engraftment, and 
thereby, the longevity of infused cells by influencing host parameters. Decreased 
immunosuppression can be applied to avoid compromising the functional activity of 
infused cells, and pre-infusion lymphoablation can decrease the risk of rejection and the 
competition for cytokines for the adoptively transferred cells (211). 
Functionality of the cultured UCB T-cells is also fundamental in evaluating the product’s 
potential to exercise effects in vivo. We performed T-cell stimulation with ionomycin and 
PMA followed by intracellular cytokine staining (TNF-a, IFN-g, and IL-2) and extracellular 
staining for the degranulation marker CD107a. In the CD4+ compartment, we found a 
tendency toward increased polyfunctionality, defined as the expression of two or more of 
the assessed factors, in culture conditions with added IL-7. There were trends toward higher 
frequencies of cells producing 3 or more factors (p = 0.063, due to the number of included 
units, n = 4, this was the lowest achievable p-value) at the expense of cells producing two 
factors, and a single factor in C6 vs. C5. In CD8+ T-cells there was a trend toward 
increased polyfunctionality with a higher frequency of cells producing 3 or more factors in 
T-cells cultured with IL-7 in C6 vs. C11 (p = 0.063). The results are shown in Figure 12. 
We then grouped culture conditions based on culture with or without IL-7, regardless of the 
IL-2 level: C5 and C11 were grouped and compared to a group consisting of C6 and C12. 
We then found an increased frequency of T-cells producing 3 or more factors in IL-7-
cultured CD8+ T-cells cultured in the presence of IL-7 (p = 0.027), indicating increased 
polyfunctionality. See Figure 12. 
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It is encouraging that the observed polyfunctionality was present in both the CD8+ and the 
CD4+ T-cell compartment in cells cultured according to the potential new expansion 
protocol (C6), with IL-7 in addition to low-dose IL-2. This might imply a better chance of 
long-lasting immune responses, as previous reports have found that immune defense 
against infection is superior in mice with more polyfunctional T-cells (293), and that the in 
vitro functionality is superior in polyfunctional T-cells regarding the level of cytokine 
production and degranulation, and the magnitude of CD40L expression (294). Also, IL-7 
treatment has been shown to augment the number of high-quality polyfunctional pathogen-
specific CD8 T-cells of a non-exhausted phenotype in mice (295), supporting our 
observation of an increase of polyfunctionality in cells cultured with IL-7. Polyfunctionality 
is thought to be associated with increased efficacy in a potential therapy situation, as 
polyfunctional T-cells have been shown to be more effective in preclinical studies of ACT 
of viruses and malignancies (296, 297).  
In scientific paper V we present the results of clinical treatment with the cultured UCB DLI 
in four patients. They received this treatment due to increasing recipient chimerism (n = 2), 
MRD (n = 1) or graft failure (n = 1). The first three patients received units cultured 
according to the first protocol, where only high levels of IL-2 was used (C11); while the 
last patient received cells cultured with the lower dose of IL-2 combined with IL-7 (C6). 
The patients were aged 17-52 years, two were females and two were males. They suffered 
from Pre-B ALL, AML and paroxysmal nocturnal hemoglobinuria with suspected 
development of MDS, respectively. The first patient received a DCBT, while the remaining 
three patients underwent single UCBT. All the patients received myeloablative conditioning 
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Figure 12. Median frequency of 5 experiments is presented for C5, C6, C11, and C12 (left), and for 
cultures grouped according to the absence (C5 and C11) and presence (C6 and C12) of IL-7 (right) for 
total CD3 + , CD3 + CD4 + , and CD3 + CD8 + cells positive for 0, 1, 2, 3, or 4 of the factors. The bottom 
graph shows the different combinations of factors included in the analysis.  
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treatments. The first patient received 4 doses of cultured UCB DLI with a cell dose ranging 
from 5 × 103 to 5 × 105 CD3+ cells/kg patient weight. The second patient received three 
doses, 1 × 105 - 1 × 106 CD3+ cells/kg, and the third and fourth patients each received one 
dose of 1 × 105 CD3+ cells/kg patient weight. The low starting dose used in the first patient 
was chosen in consideration of the possibly increase of toxicity risk due to 1) the activated 
phenotype of the cells and 2) the presence of HLA mismatches. 
There were no acute adverse reactions observed at infusion of UCB DLI. We did notice 
positive clinical events that may indicate benefit of the treatment in two of the patients: 
Patient 3, treated with UCB DLI because of mixed chimerism, had decreased levels of 
recipient cells in both the CD19+ cell lineage and, after an initial rise, also in the CD3+ cell 
lineage, in temporal association with the infusion (Figure 13). Patient 4 received UCB DLI 
because of the recurrence of detectable MRD (Figure 13). After a single UCB DLI dose, no 
MRD was detectable for several months. It should be noted that the MRD was already 
negative just before infusion. This was not known at the time, due to the inherent delay of 
test results. Unfortunately, the patient had a hematological relapse later without any 
preceding molecular signs of disease recurrence. It is debatable whether the patient would 
have benefited from additional UCB DLI infusions following the first, to prevent relapse. 
Due to the small material, and the variability of chimerism development and transformation 
of a detectable MRD to overt relapse, there is no certain causal association between the 
positive developments perceived in the patients and the UCB DLI treatment. There were no 
signs indicating possible benefit of the treatment in the two remaining patients. 
We were unable to track the infused cells as they were derived from the original UCB graft, 
preventing detection with chimerism analysis. Additional manipulation of the cells enabling 
tracking was judged inadvisable. However, if cell tracking could be used in the future, this 
could help us to assess associations between UCB DLI treatment and clinical symptoms 
indicating effects. Also, to track the in vivo presence of the transferred UCB DLI cells 
could be of great interest, since the longevity of the cells is uncertain (as related to the risks 
of cytokine deprivation and exhaustion after in vitro culture discussed above) (10, 11, 211). 
There are non-toxic and efficient cell labeling systems that could be considered in the 
future for further studies (298). 
A known treatment risk with conventional DLI is the induction and exacerbation of GVHD 
(189-192, 195). A study performed at our center has shown that 34% of the DLI recipients 
included did develop acute GVHD (190). It can be speculated that this risk increases with 
treatment with activated lymphocytes, due to the lower activation threshold in activated 
cells. However, there are data indicating that cultured and in vitro activated T-cells are 
actually less alloreactive than untreated T-cells (283, 284). A clinical study of activated 
conventional DLI treatment did not show increased GVHD incidence (299). In the present 
study, we saw no certain GVHD in the included patients. One patient (patient 2) had 
symptoms consistent with acute GVHD, but these symptoms predated the UCB DLI 
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infusions and could have been caused by an adenovirus infection the patient was suffering 
from at the time. Unfortunately, because of the patient’s poor status, the diagnosis could not 
be clarified. 
 
As discussed above, the cultured T-cells in all the UCB DLI products had an activated 
memory T-cell phenotype. The CD4+/CD8+ T-cell ratio differed between the units used in 
the study in scientific paper V. It was found to be higher in the units given to patients 3 and 
4. However, with only 4 patients, no conclusion can be drawn regarding the in vivo effects 
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Figure 13. Chimerism development and immunosuppressive treatment of Patient 3 and 
Patient 4. a), c) Chimerism development the CD19+, CD3+ and CD33+ cell lineages in 
peripheral blood, presented as percentage of recipient cells. Development of MRD is 
shown for patient 4 in c). Inset in c) shows the time between day +75 and day +180 to 
illustrate the variations of recipient chimerism and MRD. b), d) Immunosuppressive 
treatment. Arrows show when UCB DLI were given. 
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of phenotypical differences between units. 
In summary, we have found that the chosen culture strategy produces adequate cell 
numbers for an alternative ACT to conventional DLI in UCBT recipients, regardless of 
which of the cytokine combinations was used. IL-7 confers a proliferation advantage and 
allows the IL-2 concentration to be lowered below one fifth of the concentrations used 
previously. We observed changes in the phenotype of the cultured cells when IL-7 was 
added: a higher CD4+/CD8+ ratio and an increased proportion of effector memory T-cells 
in the CD4+ compartment were the most striking differences. There was also a tendency 
toward increased polyfunctionality in T-cells cultured in the presence of IL-7. 
When patients were treated with the cultured UCB DLI products, possible benefits were 
noted in two patients: one patient who had received UCB DLI cultured with the high 
concentration of IL-2 only, and another receiving UCB DLI cultured with low dose IL-2 
and IL-7. The treatment with UCB DLI was observed to be safe and feasible. Possible 
benefits of UCB DLI were seen, but no certain causal association can be found in such a 
small material. A larger study is necessary before any conclusions can be drawn regarding 
the effect of cultured UCB DLI infusions.
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IV. CONCLUDING REMARKS AND FUTURE PROSPECTS 
The discussion regarding the choice between UCB and an HLA-haploidentical relative for 
alternative donor transplantation will be continuing in the future. The results presented in this 
thesis have shown that the results in UCBT for adult patients with malignant diseases at our 
center were poorer than anticipated. Thus, it is of great importance to improve transplantation 
outcomes in this patient group. Lately, the use of allelic HLA-matching in UCBT has been 
found to improve outcomes (221), and as the cord blood banks have a large number of units 
stored, this could be applied to reach better clinical results in adult patients. Haploidentical 
HSCT using a new type of GVHD prophylaxis with post-transplantation cyclophosphamide 
is currently being implemented in many centers. This method could prove to be a valid 
alternative, as recently published studies have reported promising results (6).  
In scientific papers II and III, we presented data regarding two patients with long-term MDC. 
We described some unique characteristics of the lymphocytes of the two patients with MDC 
that distinguished them from patients with single UCB unit chimerism. The two units that 
jointly form the immune system in MDC also seemed to have different characteristics. We 
also found two possible predisposing factors for MDC development: high dose ATG and 
inter-donor HLA-C matching. These data are novel and interesting, but the scarcity of the 
material makes it necessary to interpret the results with caution. As very few reports 
regarding this chimerism state have been published, little additional information can be found 
in the literature. With regard to his current paucity of knowledge the causes and consequences 
of MDC must still be considered as unclear. As cases accumulate over time, there will be 
opportunity to study this condition in-depth and reach a better understanding of the 
underlying mechanisms.  
Results presented in this thesis and in the literature jointly indicate that the procedures used 
for culture of ACT products in UCBT can be further enhanced. Continued studies of the 
relative in vivo effects of different memory and effector phenotypes are warranted. New 
strategies for the culture of UCB T-cells should be investigated, to design T-cell products that 
are well adapted to in vivo demands. Different cytokine combinations, and different cytokine 
concentrations also merit further studies in order to improve the cultured products. Artificial 
manipulations to induce a more naïve phenotype, such as induction of telomerase expression, 
and of the expression of homing markers that enable migration to secondary lymphoid 
tissues, are potential strategies. Labeling the cultured products to enable tracking of the 
infused cells could be another valuable approach to improve evaluation of treatment effects. 
Another interesting future perspective could be to introduce new concepts into UCB ACT, 
like CARs or post-infusion activating BiTE antibodies. A small number of studies of CARs 
in the UCB settings have been published with promising results. 
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